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1. INTRODUCTION 
  
 “Survival of the fittest”  this is a phrase describing the mechanism of natural 
selection.This is the  law of nature which admits all the organism from unicellular  to 
multicellular. Here the  word fitness includes both the physical and mental wellness. 
Being healthier with out any illness must be the precursor for the evolution of different 
type of medical system in the world. Among all the medical systems in the world, siddha 
system of medicine arised from India has its uniqueness in its basic science, healing 
methods, and simple diagnostic theories. 
 
Siddha system plays a wide ranged role in the field of pediatrics. It ensures the 
health of the children with its astonishing herbalformulations right from their birth, to 
prevent the illness. Children health reflect the National health and wealth and they are the 
most vulnerable group in the society. They can become ill easier since they aren‟t built 
with a good immune system and they are exposed to several pathogens from the 
surrounding environment. Children are prone to many diseases among that common cold 
is an illness, which the child experiences the most often.Colds also involve the sinuses, 
ears, and bronchial tubes. The symptoms of a common cold includes  sneezing, runny 
nose, nasal obstruction, sore or scratchy throat, cough, hoarseness, and mild general 
symptoms like headache, feverishness, chilliness, and not feeling well in general.  
 
Colds last on average for one week. Mild colds may last only 2 or 3 days while 
severe colds may last for up to 2 weeks.A cold is a milder illness than influenza. 
Influenza typically causes fever, muscle aches, and a more severe cough. However, mild 
cases of influenza are similar to colds.Adults average 2 to 3 colds per year and children 6 
to 10, depending on their age and exposure. There are over 100 different cold viruses.  
 
Rhinoviruses are the most important and cause at least one-half of colds.Cold 
viruses can only multiply when they are inside of living cells. When on an environmental 
surface, cold viruses cannot multiply. However, they are still infectious if they are 
transported from an environmental site into, the nose.Newborn children acquire 
temporary immunity to cold viruses from their mother. By six months, this immunity has 
waned, and children are then susceptible to the over 100 cold viruses.Children have close 
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and intimate contact with their parents and other adults and children.Young children are 
not able to practice good personal hygiene, such as hand washing and covering coughs 
and sneezes. 
 
Sinus and ear drainage passages and bronchial tubes are small in children and 
easily obstructed by mucus and mucosal swelling.These factors combine to make children 
very susceptible to colds and the primary reservoir for cold viruses.Children are 
particularly at risk for virus infections, which affect the lower airway such as pneumonia 
and bronchiolitis and to middle ear infection (otitis media). Sinus development is 
incomplete in young children, but they also develop viral and bacterial sinusitis. 
 
WHO (2009)report stated that children below 5 years of age suffer about 5 
episodes of ARI per child per year.This is responsible for about 20-40% admissions to the 
hospitals.  Approx. 1 in 4 or 22.79 % or 62 million people in USA are affected by this 
common cold. Antibiotics are ineffective and should not be taken for common cold 
prevention is the treatment.over use of antibiotic causes of an increase in more resistant 
strains of bacteria. 
 
Common cold can lead to the development of complications such as pneumonia; 
acute bronchitis.There is currently no cure for the common cold. Treatment includes 
measure to help releive symptoms and keep the body as strong as possible to minimize 
the risk of developing complications. Balavagadamisoneof the literature in Siddha system 
of medicine which deals with Pediatric diseases and its management. Balavagadam has 
got more importance than any other branches of medicine in Siddha system since it deals  
with the children diseases. This is evident from the classification of diseases described from 
birth to late childhood and their treatment with specific herbs which is a distinct feature 
of Pediatric Medicine in Siddha system. 
 
Kanam has been classified into24 types in siddha system. Neerkanamaantham is 
one among them. As per Siddha literature, the disease NEERKANAMANTHAM is due 
derangement of three humours of mother which affects the constitution of children.  It 
affects the upper respiratory trac tcausing cough, fever, irritation of throat, lack of appetite 
and  dysuria. Neerkanamaantham is a disease to give more trouble some in childhood 
(3to7yrs of age group). Since the pediatric population is more prone to these type of 
3 
 
infections, and their body, mind, education are affected the most , I have selected this 
topic for my thesis work . 
 
Antibiotics are ineffective and the child becoming resistant to it on continous 
consumption  and there is a need of higher dosage for the recovery in relapsing 
conditions, which  may harm the kid infuture, A scientific research of available Siddha 
literature may bring us precious truths, methods of preparation of miracle medicines and 
this would be valuable contribution to the diseases  in the medical world. In Balavagadam 
a sastric siddha formulation Karai rasayanam is exclusively specified for 
NEERKANAMANTHAM which is not common in practice .The main ingredients of 
karai rasayanam, are karai fruit, cow milk, ghee, sugar which is purelyherbal, and it is not 
taken in trial before. Hence the author have selected KARAI RASAYANAM a herbal 
formulation as  t r i a l  d ru g to evaluate its efficacy in the treatment of 
Neerkanamaantham. 
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2. AIM AND OBJECTIVES 
 
AIM  
  The aim of the study is to evaluate the disease NEER KANA MAANTHAM 
clinically with the trail drug KARAI RASAYANAM. 
 
OBJECTIVES: 
  To review the literature of the disease Neer Kana Maantham in Siddha and 
Modern Medicine aspect 
  
To compare the aetiology, incidence,clinical features, treatment, prognosis and 
complications of Neer Kana Maantham with acute Naso Pharyngitis (common cold) in 
Modern Science. 
  
To know the predominance of disease age, sex, climate, immunization history and 
socio economic statusare considered. 
  
To Study the Neer kana maantham based onsiddha parameters such as deranged 
mukkuttram, poripulangal and ezhuudalkattukal and envagai thervugal. 
 
To study the Pharmacological activity, Physico chemical analysis, Chemical 
analysis of the trial drug Karai rasayanam. 
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3. REVIEW OF LITERATURE 
3.1 SIDDHA ASPECT 
fzk; 
 
fhg;G nra;As; :  
 
“#l;Rkkha; juzpapy; rpRf;fSf;Nf jhd; 
          ePjpajha; te;jlUk; Njhlk; jd;id  
          epjhikjha; ghbajd; topfnsy;yhk; 
          Xjp itj;j FU nkhopa;ia cw;Wzh;e;J 
          cyfkjpy; gz;bjh;fs; mwpe;Jnra;a  
          ghjpkjp jhpj;j mad; kfDk; fe;jd;  
          guhgudhk; Iq;fuid gzpe;jpl;NlNd” 
 
,ay;(Definition):  
khjhf;fspd; gpjhf;fspd; ehj tpe;Jf;fslq;fpa thjhjp Njh\q;fspdpd;W 
cw;gj;jpahfpf; fUg;ghraj;J rpRitg; gw;wp mr;rpRthdJ VOtif jhJf;fSk; 
td;ikailAq;fhyj;J mij Nehahy; tUe;jr; nra;Ak; Neha;. 
           (T.V.rhk;grptk; gps;is) 
fz Nuhfk;: 
Foe;ijfSf;F fzr;#l;bdhYk; ghypd; Fw;wj;jpdhYk; tapW 
Nfhshwile;J clk;gpy; fdg;Gz;lhfpr; Ruk;, tpau;it, euk;G typ Kjypad 
Vw;gl;L vYk;G FWfp clk;G ,isj;J tUk; Neha;. 
 
fiz Neha; cw;gj;jp 
 “G+q;Foy; khNj Nfsha; 
Gjy;tUf;F Mz;L nrd;why; 
ePq;fUk; fizapd; Njh\k; 
 epiwe;jNjhu; euk;ngy;yhk; 
jhq;fpNa epd;W jhDk; 
rhUNk Cidg; gw;wp 
ahq;Fs nuj;j nky;yhk; 
mKjd; cz;Z nkd;Nw… 
      epiwe;j njhU Mz;bd; Nkyha; 
      gz;LNru; ghyu; nka;apy; 
 gd;dpnuz;lhz;L epw;Fk; 
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      Fd;wpdpy; cikahs;f; fPrd; 
     Fwpj;jpij ciuj;jhnud;nw” 
 
ghyUf;F xUMz;L nrd;why; fizapd; Njhlk; vOfpwJ. ,j;Njhlk; 
euk;ngy;yhk; jq;fp epd;W Cid gw;Wk;. ,jdhy; uj;jk; tw;Wk;. ,g;gb te;j 
fizNjhlk;> vOe;J nghq;fp ghyfdpd; clk;gpy; 12 Mz;L epw;Fk;. Fd;wpd; kPJ 
tpahgpj;Js;srptgpuhd; cikahSf;F ,ij ciuj;Js;shu;. 
                  
    -(Foe;ij fiz Neha; kUj;Jtk;) 
fh;g;gr;R+L 
„njhifahd fzq;fs; vy;yhk; fh;g;gr;R+L” 
                                    -(mNahj;jpjhrh; ghythflk;) 
 
fh;g;gr;R+L Neha; tu fhuzq;fs; 
1. fytpapy; Vw;gLk; tpfw;gq;fs;. 
  2. Rf;fpy> RNuhzpjq;fspd; tpfw;gq;fs;. 
3. fUTw;w jha;khh;fspd; czTKiw> nray;ghLfs; ,tw;wpd; tpfw;gq;fs;. 
 
fytpapy; Vw;gLk; tpfw;gq;fs;. 
1. vz;nza; Nja;j;J %o;fpagpd;> clNd czT mUe;jp> cwf;fk;   
  nfhs;tjhy; clypd; gpj;jNjhlk; mjpfhpf;Fk;. mNj Neuj;jpy;; cwT  
  nfhs;Sk;NghJ cz;lhFk; fUTf;F fzk; cz;lhfyhk; vd;W  
  fUjg;gLfpwJ.  
  khe;jfzk;         - (Mjhuk;: ghythflk;) 
 
Rf;fpy> RNuhzpjq;fspd; tpfw;gq;fs;. 
1. fzkhdJ> khjhgpjhf;fsp;d; ehjtpe;Jf;fSs; mlq;fpa thjhjp  
  Njhlq;fspypUe;J cw;gj;jpahfp> fUg;igapd; rpRitg;gw;wp> mr;rpRtpdJ  
  rg;jjhJf;fSk; td;ikia milAk; fhyj;jpy; ghjpf;fpd;wJ. (Njhlq;fs;  
  tpUj;jp milfpd;wd).  
                             -(Mjhuk;:IPtul;rhkph;jk;) 
„Rf;fpyj;jpy; RNuhzpjq; fyf;Fkd;W 
GFe;jpLk; tpahjp %d;Wk;” 
                                 -(jd;te;jphp ehb E}y;) 
 
fUTf;F moy;jhJtpidr; Nrh;g;gJ Rf;fpykhFk; mjid gpd;tUk; E}y;fs; 
njspthf $Wfpd;wd. 
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„ghd;ik vd;w tpe;jq;Nf A+Wk;NghJ 
      ghAklh td;dpNahL thAjhNd” ; 
         -(mfj;jpah; ty;yhjp ehb E}y;) 
„cd;dpa fh;g;gf; Fopahk; ntspapNy 
 gd;dpa ehjk; gfh;e;j gpUjptp 
td;dpAk; thAT khapUQ; Rf;fpyk; 
      kd;dpa rkdha; tsh;f;F KjfNk”. 
                                    -(jpUke;jpuk;) 
 
fUtpw;F> tpe;JtpypUe;J - thjk;> gpj;jk; vd ,uz;L jhJf;fSk; cjfePh;> ehjk; 
,tw;wpypUe;J fgKk; fpilf;fpwJ vd fUjg;gLfpwJ. 
 
mNj ghlypy;> 
 „cjfKjpu KWq;fdy; thAthy; 
 rpj FW kq;fq;fs; nra;J Kbj;jpLk;‟ 
 
vd Fwpg;gpLtjhy;cjfkhfpa ePh;> jP kw;Wk; thAtpd; jd;ikahy; nre;ePuhf 
khwp kw;w cly;jhJf;fshd Cz;> nfhOg;G> vd;G> %is> Rf;fpyk; ,tw;iw 
cz;lhf;Fk; vd fUjg;gLfpwJ.vdNt Rf;fpy> RNuhzpjq;fspd; FiwghL> 
cjfePhpd; FiwghL Nghd;wtw;why; fUtpd; caph;j;jhJfspy; xd;whd moy; 
ghjpg;giltjhy; fzk; Vw;gLfpwJ. „fh;g;gr;R+L‟ vd miof;fg;gLtjw;Fk; mJNt 
fhuzk; vd fUjyhk;.  
 
3;. fUTw;w jha;khh;fspd; nray;ghLfs;: 
  
„igau ty;F yhSk; grpAldpUe;j jhYk; 
 Ja;aNjhh; Fotpfl;F fzq;fSe; Njhd;Wkd;Nw” 
-(ghythflk;) 
      
 fUTw;w jha;khh;fspd; czT gof;ftof;fq;fs;> nray;ghLfs; 
Nghd;wtw;why; jhapd; clypy; moy;jhJ ghjpg;gile;J mJ fh;g;ghraj;ijAk; 
jhf;Fk; vd [Ptul;rhkph;jk; vd;w E}ypy; $wg;gl;Ls;sJ. vdNt fUtpd; 
moy;jhJtpy; FiwghL Njhd;Wtjhy; mjd; cly; jhJf;fs; ghjpf;fg;gLfpd;wd. 
,JNt „fh;g;gr;#L‟ vd miof;f fhuzkhfTk; mike;jpUf;Fk;.  
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tUk;top nghWj;J     
1. khe;jNehapd; njhlh;r;rpahfcz;lhtJ 
2. taijg; nghWj;J  
  3-7tajpy; cz;lhjy; 
  ghYk;NrhWk;cz;Zk; gUtj;jpy; cz;lhjy;; 
 
khe;j Nehapd; njhlh;r;rpahf fzk; Njhd;Wk; tpjk;: 
khe;jk; 
NtW ngah;fs;: 
ke;jk;> myrk;> myrfk; vd gps;isg; gpzp 
kUj;Jtk;E}ypy;Fwpg;gplg;gl;Ls;sJ. 
 
,ay;: 
ke;j ,ay;GilaJ khe;jk; vdg;gLk;. ke;jk; vd;gJ cUtepiyapy; cly; 
epiyapy; ke;jk;. mUtepiyapy; mff;fUtpfshfpakdk;> Gj;jp> rpj;jk;> mfq;fhuk; 
Mfpa midj;J me;jf;fuzq;fspYk; ke;jk; vdFoe;ij 
kUj;Jtj;jpy;nfhLf;fg;gl;Ls;sJ. cz;l czT nrhpahky; tapw;wpy; Gspj;J 
tapW cg;gp ,iue;Jke;jj;ij cz;lhf;fp the;jpiaAk; 
fopr;riyAk;cz;lhf;fpJd;gj;ij Vw;gLj;Jk; Neha; vd gps;isg;gpzp 
kUj;Jtj;jp;y; Fwpg;gplg;gl;Ls;sJ. 
 
Neha; tUk; gUtk;: 
jhyg;gUtk;> rg;ghzpg; gUtk;> Kj;jg; gUtk;> tUifg;gUtq;fspy; 
cz;lhff;$ba NehahFk;.Foe;ijapd; Kjy; Mz;by; ,Ue;J %d;W Mz;Lfs; 
tiunjhlUk; vd Foe;ij kUj;Jtk; kw;Wk; jd;te;jphp Foe;ijthflj;jpy; 
Fwpg;gplg;gl;Ls;sJ. ,e;Neha; 3 khjk; Kjy; 7 taJ tiu tuf;$baJ. 
ghy;kl;LNk Fbf;Fk; gUtk;> ghYk; NrhWk; cz;Zk;gUtk;>NrhWkl;LNk cz;Zk; 
gUtk; Mfpa %d;WgUtq;fspYk; khe;jk; Vw;gLk; vd 
gps;isg;gpzpkUj;Jtj;jpy;Fwpg;gplg;gl;Ls;sJ. 
 
Neha; tUk; top: 
Foe;ij ePh;epiyfspy; gOj;J> cjph;e;j rUFfs; tpOe;JmOfpapUf;Fk; 
ePiuf; Fbj;jy;.vUikg;ghy;> Gspj;j vUikNkhh;> vUik nea;> 
thiog;gok;>khk;gok;> Njq;fha;> ,sePu;> fliy> nty;yk;> 
fhl;Lj;Jtiu>nkhr;irf;nfhl;il> Gspaq;nfhl;il> gUg;G cUz;il> 
khtpdhy;nra;ag;gl;l nghUl;fs;> mjpurk;> thAg;nghUl;fs;> NrhW,itfis 
mjpfkhf cz;zy; Kjypa fhuzq;fshy; khe;jNeha; cz;lhFk; vd Foe;ij 
kUj;Jtk; Fwpg;gpLfpwJ.ke;jg; nghUshfpavUikg;ghy;>nea;>thiog;gok;>khk;gok;> 
fliy.nty;yk;. khkprk;. gUg;G cSit kPd;, tuhy;kPd;,nfz;ilMfpatw;iw 
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Foe;ijfs; cz;Zk;NghJ khe;jNeha; cz;lhFk;vd jd;te;jphp Foe;ij thflk; 
$WfpwJ.ghfw;fha;> Riu> cSe;J> Cd;> ngupa cSit kPd;. this kPd;>gd;wp 
,iwr;rp> tpuhy; kPd;> nfz;il kPd; Mfpa MfhjnghUl;fis cz;gjhYk; 
khe;jNeha; cz;lhFk; vdgps;isg;gpzp kUj;Jtk; Fwpg;gpLfpwJ. 
NkYk; NrhW kl;LNk cz;Zk; gUtj;jpy; Foe;ijapd; czTFw;wj;jpdhYk; 
cztpd; NtWghl;lhYk; khe;jk; Vw;gLk;.Foe;ijapd; J}a;ikaw;w jd;ik> rhpahd 
Neuj;jpy; rhg;gplhJNeue;jtwp rhg;gply;> Rj;jkw;w czTg; nghUl;fisr; 
rhg;gply;>clk;gpy; Nghjpa Cl;lr;rj;J ,y;yhj epiy Mfpafhuzq;fspshYk; 
,;ggUtj;jpy; ,e;Neha; tUk;.cztpdhy; kl;Lkpd;wp nraypd; NtWghl;lhYk; khe;j 
Neha;Foe;ijiaj; jhf;Fk;. tWik>grp> Jauk;> kdf;ftiy>gak;> Nfhgk;. ,r;ir 
Nghd;w czh;Tfshy; Foe;ijahdJjhf;FWk; NghJ czTnrhpf;Fk; jd;ikapy; 
khWghL epfo;eJkhe;jk; cz;lhfpwJ vd gps;isg;gpzp kUj;Jtk; $WfpwJ. 
Nkjpg;ghy;> nea;> fjypg;gok;> Njq;fha;> ,sePu;> nty;yk;> Gspj;jNkhu;> khkprk;> 
fdpfs;> cSe;J> nkhr;ir>Gspaq;nfhl;il cSit> nfz;ilkPd;> ghfy;>Riu 
Kjyhd thAg; gz;lq;fisghy; nfhLf;Fk; khju;fs; kpFjpahf cz;lhy; 
my;yJFoe;ijfs; mjpfkhf cz;lhy; khe;j Neha; cz;lhFk; vdMtp mspf;Fk;  
mKj Kiw RUf;fj;jpy; Fwpg;gplg;gl;Ls;sJ.  
 
czTg;gof;fj;jhy; khe;jk; Njhd;Wjy;: 
  
cz;Zk; cztpd; nrhpkhdj;jpw;F> 
  rkhdd;  - thjk;> 
 mdw;gpj;jk; - gpj;jk;> 
  fpNyjfk; - fgk;> 
 Mfpa %d;wpd; ,ay;ghd msT Kf;fpakhdjhFk;. 
 
mdw;gpj;jk;  - czTg;nghUs;fspd; nrhpkhdj;jpy; Kjd;ik gq;F  tfpf;fpwJ.  
fpNyjfk;  - cz;Zk; cztpid nkj;njd nra;Ak;.  
rkhdd;  - Nkw;fz;l ,uz;ilAk; rkepiyg;gLj;jp> rhpahd    
     nrhpkhdj;jpw;F cjTfpwJ.  
 
khe;jk; njhlh;e;J epiyg;gjhy; cztpd; rhuk; clw;fl;LfSf;F 
Nrh;tjpy; njha;T Vw;gLfpwJ. (tpahddpd;njhopy; ghjpj;jy;)rhuk; nre;ePuhf 
khWk;; Ntiy ghjpj;jy; (,uQ;rf gpj;jj;jpd; njhopy; ghjpj;jy;)kw;w 
clw;fl;Lfis Nghlzpg;gjpy; rpukk; cz;lhjy;clw;fl;Lfspd; td;ik 
Fiwjy;, fzj;jpd; FwpFzq;fs; Njhd;Wjy;. 
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fzk; Njhd;Wk; taJ: 
„vd;dNt fz%d;W tUle; njhl;Nl 
Vohz;L kl;Lf;F kpUf;Fq; fhyk;”  
- ghythflk; 
taijg; nghWj;J 2 fUj;Jfs;: 
     1. 3-7tajpy; cz;lhjy; 
     2. ghYk; NrhWk; cz;Zk; gUtj;jpy; cz;lhjy; 
 
 ;Neha; tUk; top: 
 „IaJ $bw; nwd;why;  
  mhpitah; Jaue; jd;dhy; 
  nra;a gw; GdyUe;jpr;  
nrwpry Njhle; jd;dhy; 
  igau ty;F yhSk;  
  grpAl dpUe;j jhYk; 
  Ja;aNjhh; Fotp fl;Ff;  
fzq;fSe; Njhd;W kd;Nw”.ghythflk; 
 
IaJ $bw;nwd;why;: (Iak; - caph; jhJ) 
 
Iaj;jpd; ,aw;if epiyfs;> mjd; kpFFzk; Nghd;wtw;iw xg;G Nehf;Fk; 
nghUl;L fPo;fz;lthW njhFf;fg;gLfpd;wJ.  
 
jd;ik:  
- jz;ik> nea;g;G 
- ke;jk;> tOtOg;G 
- nkd;ik> jpz;ik 
 
thOkplk;: 
- rkhdthA> ROKid 
- Mf;fpid>khh;G 
- ehf;F> cz;zhf;F 
- nfhOg;G> kr;ir 
- FUjp> euk;G> vYk;G 
- %is> ngUq;Fly;> fz;> fPy;fs; 
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,aw;ifg; gz;G: 
- epiyj;jy; 
- nea;g;G  
- fPy;fspd; mikg;gpd; fl;Lfs; 
- nghiwAilik ( grp> ePh;Ntl;if Jauk;> fyf;fk;> ntg;gk; 
Nghd;wtw;iw nghWj;Jf; nfhs;Sjy;) 
 
Ia kpFFzk;: 
- mf;fpdp ke;jg;gly; 
- tha;ePH Cwy;,,iug;G> cg;gprk;> ,Uky;> kpFJ}f;fk; cz;lhjy;. 
- Cf;fk; Fiwjy; 
- cly; fdkhf Njhd;WtJld; ntz;zpwj;ijAk;> Fsph;r;rpiaAk; 
miljy;. 
- cly; Kw;Wk; cs;s fl;Lfs; jsuy; 
 
mhpitah; Jaue; jd;dhy;: 
mhpit - ngz;fspd; gUtq;fspy; xd;W. 
20-25 tajhdJ kfsph; kfg;NgW milAk; nghJthd fhyk; vd;gjhy;> 
ghlypy; mhpit vd;w thh;j;ijia Nkw;nfhz;bUg;gij czuyhk;. mg;gUtj;jpy; 
kfsphpd; Jd;gq;fshd cly;eyf;FiwT> Foe;ijfSf;F gy ,lh;ghl;bidAk;> 
Fwpg;ghf fzj;jpidAk; cz;lhf;Fk;;. 
 
nra;a gw;GdyUe;jp nrhpry Njhle;jd;dhy;: 
 gy;NtWtifg;gl;l ePhpid mUe;Jtjhy; ryNjhlq;fs; cz;lhfp epiyj;J 
fzNeha; Njhd;Wk; vd;gJ nghUshFk;. 
 mj;jifa ePhpd; jd;ik> Fbj;jYf;F Mfhj ePH vd rpj;jkUj;Jtj;jpy; 
$wg;gl;Ls;s fUj;Jfisf; fhz;Nghk;. 
 
ePhpd; jd;ik: (rpj;jkUj;Jthq;f RUf;fk;) 
ePuhdJ kdJf;F fspg;igAk;> epiwitAk; cz;lhf;FtJ kl;Lkd;wp 
cl;nfhs;Sk; cztpid ed;wha; clypw; gutr; nra;J clw;F td;ikiaj; 
jUk;. NkYk; cz;l fbd czTg;nghUl;fis nrhpg;gpf;Fk;.  
ePUf;F jdpFzk; ,y;iy. mJ jq;Fk; ,lj;jpd; NtWghLfshNyNa 
ntt;NtW Fzq;fis milfpd;wJ.,jid> 
„jz;zPh; Fznky;yhe; jhd; Nfs; klkapNy 
kz;zpd; Fzky;yhy; kw;Wz;Nlh? ‟ 
                 - Njud; nghUl;gz;G 
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Fspay; Fbj;jYf;F Mfhj ePh;: 
 
 „re;jpuh jpj;jh; tsp rhuhj ePh; GOJh;f;  
 fe;jkjp NrW fdg;gpiyA - jphpe;j ePh; 
 jq;FRit apy;yh ePh; rhw;Wkpit ];ehdgh 
 dq;fSf;fh fhTwpNeh ahk;” 
- gjhh;j;j Fz rpe;jhkzp 
 
jpq;fs;> QhapW ,tw;wpd; fjpnuhsp;;; fhw;W ,itfs; mZfhjJk;; fpUkp> 
Jh;ehw;wk;> NrW jbj;jy;> rUF cjpuy;> Ritapd;ik vd;Dk; ,itfs; 
nghUe;jpaJk; Mfpa ePh;> Fspay;> Fbj;jy; ,itfl;F MfhJ. ,ij cz;zpd; 
Nehia cz;lhf;Fk; 
NkYk;> 
 
„Jiyahf; fpzNw fae;jpul;Lk; ”  
- ,iwg;gpy;yh fpzw;WePh; fgg;gpzp cz;lhf;Fk;. 
 
„tsh;f;FQ; Ruj;ij rU$wy; ” 
    - rUF Cwpa ePh; Ruk; tsh;f;Fk;. 
 
„khwhf; FsNk tpahjpAz;L ”  
- gad;gLj;jhj Fsj;JePh; tpahjp cz;lhf;Fk;. 
 
mt;thW gy;NtWgl;l ePhpid mUe;Jtjpdhy; ryNjhlk; Vw;gl;L fzNeha; 
Njhd;Wk; vd;W $wg;gLfpd;wJ. 
 
igau ty;FyhSk; grpAldpUe;jjhYk;: 
 
(igau - #y;nfhz;l: ty;Fyhs; - #Yw;w ngz;fs;). 
 
#Yw;w ngz;fs rhptpfpj cztpid cz;zhjjhy; mth;fspd; cly;eyd; 
Fd;wp mJ Foe;ijfspd; tsh;r;rpiaAk; fzNehiaAk; Njhw;Wtpf;Fk.; 
 
gpw E}y;fs; fUj;J : 
jpUts;Stehadhh; ,aw;wpa etuj;jpdrpe;jhkzp 800 y; $wpathW je;ijapd; 
Ntl;ifahy; gpz;lk; fdypy; mbgl;L fzk; tUtjhf $wg;gl;Ls;sJ. 
 “ghuhd nfw;gntl;il kPUk; gf;Ftj;jpy; 
 Ntuhd tphpe;J ntspg; gl;L Nahdp tpOe;j njd;whw; 
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 fhuhd gpz;lq; fdypyb gl;Lf; fhe;jpdpdhw; 
$uha; fzRu nka;J nkd;Nwahd; $wpNdNk” 
 
jd;te;jphp itj;jpak; vDk; E}y; fzkhdJ G+h;tn[d;kq;fspy; nra;j 
jPtpidfisj; je;ijahfTk;> ,g;gpwg;gpy; nra;Ak; jPtpidfisj; jhahfTk; 
mile;J „raf; Fkhud;” gpwf;fpwhd; vd;W $WfpwJ. 
„rPhpa njhd;ik nra;j jPtpid je;ijahfg; 
  ghhpypg; gpwg;gpw; nra;j ghtNk jhajhfg; 
  Nghpar; raf; Fkhud; tpwe;jpyh fpw kj;jg;Ng 
  fhhpa nrtpypj; jhaha; „fzk;” ngw tsUk; ehspy;….. 
 
Fk;gKdp ghythflk; - fizapd; tuyhW 
 
juzpjdpNyAW NraUlYjdpNy tU fizNuhf tuyhW Nfs; 
 fdpTngW nfw;gkpy; nuzkJ #bdhy; NghfkJ kpF #bdhy; 
tputpDlNd gy Njhrkjpdhypdp jhapDl ghy; Nttpdhy; 
tps;S gy tprkjhy; jPapDl fhq;ifahy; ,sntapY nfhs;syhYk;  
cuAkhfhukJ FiwAkjpdhypdp cz;Z ghy; Ngjkjpdhy;  
cwthfNt fLk; #LlNd cz;zyhy; Gspj;j tif cz;zyhYk;  
GiuNkT mjpf ngUk; fhutif jpd;gjhy; mj;jpaJ #L kpQ;rp 
GfOupa khkprk; fUfpaJ nuzNk tw;wpaJNt naOk;Gk;. 
 
Neha; tUk; top 
 
cs;sk; njsptw;wpUf;Fk; jhapd; cly;epiy ghjpf;fg;gLk; NghJ> mtis 
mz;b thOk; Foe;ijapdJ clYk; ghjpf;fg;gl;L mtjpAWfpwJ. mjpfkhd 
#Nlw;gLk; NghJ rpNyj;Jkk; mjpfkhfr; Nru;tjhYk;> jha;fjpfkhd Jauk; 
Vw;gLtjhYk;> gy tifahd ePupidg; gUFtjhYk;> mjpfkhd ryNjhlk; 
Vw;gLtjhYk;> grpAldpUf;Fk; jhapd; ghiy cz;gjhYk; Foe;ijf;Ff; fz 
Neha; Vw;gLfpwJ.jha; njhLfwpifs mjpfkhf cz;zy;> jhfk;> grp Mfpa 
Jd;gq;fisr; rfpj;jy;> jha; je;ijaupd; Kf;Fw;wq;fs;> Njhlq;fs; Mfpa 
fhuzq;fshy; Foe;ijf;Ff; fz Neha; Vw;gLfpwJ. [gps;isg;gpzp kUj;Jtk;] 
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fzj;jpd; tiffs;:( Types): 
gy;NtW E}y;fs; ntt;NtW vz;zpf;iffspy; fzj;jpidj njhFf;fpd;wd. 
 
1. gps;isg;gpzp kUj;Jtj;jpy; $wg;gl;Ls;s fzq;fs;-64 tiffs; 
1. tsp fzk;   33. mow; fzk; 
2. Ia fzk;   34. khe;j fzk; 
3. ePh;f; fzk;   35. gpuspf; fzk; 
4. #yp fzk;   36.. Rop fzk; 
5. kfh fzk;   37. CJ fzk; 
6. tus; fzk;   38. nfhjpg;G fzk; 
7. tPf;f fzk;   39. gpwf; fzk; 
8. mf;fu fzk;   40. ke;jhu fzk; 
9. vhp fzk;    41. ePuhk fzk; 
10. ,uj;j fzk;   42. Kf;F fzk; 
11. %y fzk;   43. Nguhk fzk; 
12. cyup fzk;   44. rpq;fp khe;j fzk; 
13. Mk fzk;   45. Rj;jp fzk; 
14. czf;F fzk;   46. ru;g;g fzk; 
15. cd;Nuhf fzk;   47. rpj;u fzk; 
16. CJkhe;j fzk;   48. Ru fzk; 
17. fug;ghd; fzk;   49. jdpRu fzk; 
18. fsp; fzk;   50. mjpRu fzk; 
19. Fly;Nrhif fzk;  51. J}q;F fzk; 
20. FlNyw;w fzk;   52. njw;fj;jp fzk; 
21. vhp fzk;    53. njw;fj;J khe;j fzk; 
22. ,uj;j fzk   54. ePuhk;g fzk; 
23. %y fzk;   55. gl;rp fzk; 
24.  kNfe;jpu fzk;   56. ghy fzk; 
25. ke;jhu fzk;   57. %yhjhu fzk; 
26. Nkf fzk;       58. thA fzk; 
27. thNte;jpu fzk;   59. thyre;jpu fzk; 
     28. tp\ fzk;    60. tp\ePu; fzk; 
     29. tp\ghf fzk;   61. tp\ khe;j fzk; 
     30. tpujp fzk;   62. tPq;F fzk; 
     31. ntg;G fzk;   63. Fd;wp mf;fu fzk; 
     32. nghUK fzk;             64. KbNyhf fzk; 
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2. Mj;kul;rhkph;jk; vd;Dk; itj;jpa rhuq;f rq;fpufk; - 23 tiffs; 
 - fe;jrhkp Kjypahh;; 
1. thj fzk;   13. gpj;j fzk; 
2. rpNyj;Jk fzk;   14. khe;j fzk; 
3. ePh;f; fzk;   15. gpusp fzk; 
4. #iyf; fzk;   16. Rop fzk; 
5. kfh fzk;   17. CJ fzk; 
6. twl;rp fzk;   18. nfhjpg;G fzk; 
7. tPf;f fzk;   19. gpwf; fzk; 
8. Mkf; fzk;   20. tul; fzk; 
9. Kf;F fzk;   21. Nghh;f; fzk; 
10. ,uj;j fzk;   22. er;R khe;j fzk; 
11. CJ khe;j fzk;   23. vhp fzk; 
12. ke;jhu fzk; 
 
3. mNahj;jpjhrh; ghythflk; 24 tif - gf;fk; - 180; gjpg;G 1992 
1. tsp fzk;     
2. mow; fzk; 
3. Ia fzk;    
4. khe;j fzk; 
5. ePh;f; fzk;     
6. gpuspf; fzk; 
7. #yp fzk;     
8. Rop fzk; 
9. kfh fzk;     
10. CJ fzk; 
11. tus; fzk;     
12. nfhjpg;G fzk; 
13. tPf;f fzk;    
14. gpwf; fzk; 
15. me;jf fzk;    
16. ke;jhu fzk; 
17. vhp fzk;     
18. ePuhk fzk; 
19. Mk fzk;   
20. Kf;F fzk; 
21. %y fzk;    
22. Nguhk fzk; 
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23. uj;j fzk;    
24. rpq;fp khe;j fzk; 
 
4. guuhr Nrfuk; ghyNuhf epjhdk; - 18 tiffs; ghly; : 271; gf;fk;- 75 
1. thj fiz   10. gpj;j fiz 
2. Ruf; fiz   11. mj;jpRu fiz 
3. twl; fiz   12. thyre;jpu fiz 
4. kNfe;jpu fiz   13. J}f;F fiz 
5. mdw; fiz   14. tPq;F fiz 
6. ntSg;G fiz   15. rj;jp fiz 
7. ,uj;j fiz   16. %yf; fiz 
8. fUq; fiz       17. kQ;rl; fiz 
9. epyf; fiz   18. ntg;G fiz 
 
5. gps;isg;gpzp thflk; - 8 tif 
1. ePh; fzk;    5. tus; fzk; 
2. %y fzk;   6. rPj fzk; 
3. ,ja fzk;   7. kfh fzk; 
4. kyf;fzk;   8. Fz;lypa fzk; 
 
6. [Ptul;rhkph;jk;> 8 tiffs; - MWKfk; gps;is mgpjhd rpe;jhkzp  
1. #yp fzk;   5. Kf;F fzk; 
2. Mk fzk;   6. Njiufzk; 
3. kfh fzk;   7. Rop fzk; 
4. fop fzk;   8. tws; fzk; 
  
7.Fk;gKdp ghythflk; - 18 tif 
1. Ruf; fiz 
2. J}q;Ff; fiz 
3. %y nuj;jf; fiz 
4. twr;rp fiz 
5. ntg;Gf; fiz     
6. mdy; fiz 
7. tPq;F fiz 
8. khe;jf; fiz 
9. kQ;rs; fiz 
10. ePy fiz 
11. rj;jp fiz 
12. nuj;jf; fiz 
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13. Nkff; fiz 
14. Mj;jp Ru fiz 
15. thNye;jpu fiz 
16. thyre;jpu fiz 
17. kNfe;jpu fiz 
18. cs;SNuhf fiz 
  
8.Foe;ij fiz Neha; kUj;Jtk; 
“ vd;wNjhu; fizfnsy;yhk; 
epd;wNgu; gjpndl;Lk; jhd; 
epd;wNjhu; gjpndl;Lk; jhd;“ 
 
1. thjf; fiz 
2. gpj;jf; fiz 
3. rpNyw;gdf; fiz 
4. Ruf; fiz 
5. J}q;F fiz 
6. %y nuj;jf; fiz 
7. twr;rp fiz 
8. ntg;G fiz 
9. mdy; fiz 
10. tPq;F fiz 
11. kQ;rs; fiz 
12. ePy fiz 
13. fopr;ry; fiz 
14. fha fiz 
15. Nkff; fiz  
16. khe;jf; fiz 
17. Rj;jp fiz 
18. ,Uky; fiz 
 
 
9. gps;isg;gpzp kUj;Jtk; 
rd;dpNjhlk;> jha;> je;ij> Nghfj;jpdhNyw;gl;l Njhlk;> jha;g; ghiyAz;l Njhlk;> 
Kd; nra;j Njhlk;> ryNjhlk; Mfpa Njhlq;fshy; 16 fzq;fSk; te;J NrUk;. 
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fzj;jpd; tiffs;: 
1. thj fzk; 
2. gpj;j fzk; 
3. fg fzk; 
4. khe;j fzk; 
5. gpw fzk; 
6. ePu;f; fzk; 
7. gpuspf; fzk; 
8. #yp fzk; 
9. Ropf; fzk; 
10. Mk fzk; 
11. twl;rpf; fzk; 
12. $u;nfhjpg;Gf; fzk; 
13. tPf;f fzk; 
14. Njiu fzk; 
15. Kf;F fzk; 
16. %y fzk; 
17. Nghu;f; fzk; 
18. tp\ fzk; 
19. ,uj;j fzk; 
20. CJ fzk; 
21. ke;jhu fzk; Mfpad 21-y; 16 kl;Lk; Foe;ijfl;L tUtdthk;. 
 
TV rhk;grptk; gps;is mfuhjpapd;gb  
fzkhdJ> khjh gpjhf;fspd; ehj tpe;Js;slq;fpa thjhjp 
Njhlq;fspdpd;W cw;gj;jpahfpf; fUg;ghraj;Jr; rpRitg; gw;wp mr;rpRtpdJ 
vOtifj; jhJf;fSk; td;ikailAq; fhyj;J mij Nehahy; tUe;jr; nra;Ak; 
Neha;. 
 
fzj;jpd; nghJ Fzq;fs; : 
1. ghy thflk; $Wk; Nehapd; Fzq;fs; 
 Foe;ijfSf;F khe;j Neha; gyKiw te;J Kw;wpYk; Fzkilahky; 
,Ug;gjhy; ,e;Neha; cz;lhFk;. 
 gpj;jkhdJ mjpfkhfp thAf;fs; jd; Ntiyia nra;a Kbahky; 
jLj;JtpLk;. mjdhy; Foe;ijfspd; clypy; Vw;gl;l #L ve;NeuKk; 
tplhJ fhZk;. 
 Ruk; fha;jy; 
 ,Uky; 
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 %r;R thq;Fjy; 
 cly; Nrhh;tiljy; 
 tapW Nehjy; 
 tapW fopjy; 
- kyk; vz;nza; frpthdjhf ,Uf;Fk; 
- rPjkhf> ,uj;jkhf (m) ,uj;jKk;> rPjKk; fye;J Ngjpahjy; 
- ghy; Nghy ntz;zpwkhf fopjy; 
- Cz; fOtpa jz;zPh; Nghy; Ngjpahjy; 
- kytha; vhpr;ry; 
- kyk; ntl;ilahjy; (kyr;rpf;fy;) : 
 cr;rpapy; Fop tpOjy; 
 Kfk; Nrhh;tile;J fhZjy; 
 Fuy; fk;kyhf NgRjy; 
 if> fhy;> Kfk; twz;L fhZk; 
 mdy; tPRtJ Nghd;W cl;Ruk; fhzy; 
 tha;ehw;wk; 
 khh;G $k;G Nghy; vOk;gp fhzy; 
 ePh; RUq;fy; 
 
fzj;jpy; xd;Wld; xd;W njhlh;Gfsw;w gy FwpFzq;fs; njhFg;ghff; 
fhzg;gLfpd;wd. mjdhy; fzj;jpy; gy Neha; epiyfs; ,Ug;gjid mwpayhk.; 
NkYk; nghJf;FwpFzq;fis gpujhdkhff; nfhz;L> fzj;jpd; rpwg;G 
Fzq;fSld; nghUj;jp (fzj;jpd; tiffs;) Nehapid fzpj;jy; rpwg;ghdjhFk;.  
gpw E}y;fspy; fhZk; fzj;jpd; nghJFzq;fis mwpe;J nfhs;Sk;NghJ> 
Nehapid Fwpj;j njspthd xg;GNehf;F nra;a KbAk; vd;gjhy; mjidAk; 
fhz;Nghk;;. 
 
2. mgpjhd rpe;jhkzp $Wk; Nehapd; Fzq;fs;: 
 khh;gpy; tPf;fk; 
 cl;Ruk; 
 Ruk; 
 twz;l kyk; 
 
3.  [Ptul;rhkph;jk; $Wk; Nehapd; Fzq;fs;: 
 Njfthl;lk; 
 tha;ehw;wk; 
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 jiyRw;wy; 
 cs;Ruk; (my;yJ) 
 tapw;wpd; Nky; RLjy; 
 kaf;fk; 
 
,f;Fzq;fs; rfy fzj;jpw;Fk; nghJthf tUk; vd mwpf. 
 
cs;Ruk; Fwpj;j tpsf;fk;: 
mf];jpah; RuE}y; 300 - „rpj;jkUj;Jtk; - nghJ‟ gf;fk; 57 - 6k; gjpg;G 
vd;w E}ypy; „RukNj fizajhFk;” vd $wg;gl;Ls;sJ.mjd; tpsf;fj;jpy; 
Foe;ijfSf;F Njhd;Wfpd;w vd;GRuk;> moy; Ruk;> khe;jRuk; Nghd;witfs; 
Foe;ijfis tUj;jkilar; nra;J> gpd;dh; fiz Nehapid gpwg;gpf;Fk;. 
 
fzk; - Ruk; njhlh;G : 
  
„fiz Nehapy; cl;Rukhf fhAk;” 
 rpj;jkUj;Jtk; - nghJ 
 “fizapy; fhe;js; kyh; Nghd;w Ruk; fhZk;” 
  
Nkw;fz;l Nkw;Nfhs;fs;> fzj;jpy; Ruj;jpw;Fk; gpw Neha; epiyfspy; 
fhZk; Ruj;jpw;Fk; NtWghL cz;L vd;gij njspthf $Wfpd;wd. 
 
(fhe;js; kyh; vd;gJ jP G+jj;Jld; njhlh;G nfhz;lJ. me;j kyhpd; my;yp 
,jo;fs; RUf;fkhdjhf fhZk.; fiz NehapYk;> njhlh;e;J cl;Ruk; cs;s 
Foe;ijfs; cly; Nrhh;tile;J fhZtjhf nghJ FwpFzj;jpy; Fwpg;gplg;gLtJ 
rpwg;ghFk;).“cl;Ruk;” vd;gJ gpw Ruq;fspypUe;J NtWgl;lJ.,r;Ruk;> cly; td;ik 
Fiwe;j Ngh;f;F ntspf;F njhpahky; clypd; cs;Ns jfpj;J> Ruk; ,Ug;gJ 
Nghd;W fhzg;gl;L> Nrhfk;> kdj;jsh;r;rp>iffhy; Xa;r;ry;> cztpy; tpUg;gkp;d;ik> 
tha;f;Fkl;ly;>vg;NghJk; Ruk; fha;tJ NghypUj;jy;>cly; nkype;J nfhz;Nl 
nry;Yjy; vd;Dk; Fwp Fzq;fis gpwg;gpf;Fk;. 
          
    - rpj;jkUj;Jtk;-nghJ - gf;fk; - 36 
 
ghythflk; E}ypd;gb ePu;f;fzkhe;jj;jpd; FwpFzq;fs;: 
“,UK %f;fpy; ePu;tbAk; 
 ,ilapy; Ruq;fhAk; 
nghUkp tapW ,iur;rYz;lhk; 
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 Nghjg; gytpj kha;f;fopAk; 
nrhUFq; fz;Zk; clk;GKfk; 
 Nrhu;e;J jiyAk; Gul;lYz;lhk; 
kUtp kaf;fk; cz;lhFk; 
tUF ePu;f;fz khe;jKNk”. 
-ghythflk; Foe;ij kUj;Jtk;  
 ,Uky;> %f;fpy; ePu;tbAk; 
 ,ilapy; Ruq;fhAk; 
 nghUkp tapW ,iur;rYz;lhk; 
 gytpj kha;f;fopAk; 
 fz;> clk;G> Kfk; Nrhu;e;J NghFk; 
 kaf;fk; cz;lhFk;. 
 
Mj;kul;rhkpu;jk; vd;Dk; itj;jpa rhurq;fpuj;jpy; 
 ,Uky;> %f;fpy; ePu;tbAk; 
 ,ilapy; Ruq;fhAk; 
 nghUkp tapW ,iwr;rYz;lhk; 
 gytpj kha;f;fopAk; 
 kaf;fk; cz;lhFk; 
 fz;> clk;G> Kfk; Nrhu;e;J NghFk;. 
 
Neha; fzpg;G:(Diagnosis) 
Piniyari muraimai is a method of diagnosing a disease. Siddha system has a very 
unique method of diagnosis. 
  “Pini” means    =   Disease 
  “Ari” means  = Identify 
  “Muraimai” means   =   Method. 
This is based upon three main principles and Envagai Thervugal.  
The three main principles are, 
1. Poriyal arithal (Inspection) 
2. Pulanal arithal ( Palpation) 
3. Vinathal ( Interrogation) 
  Physician‟s „Pori‟ and „Pulan‟ are used as tools for examining the „Pori Pulan‟ of 
the patients. The above principles correspond to the methodology of 1.Inspection, 
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2.Palpation and, 3.Interrogation in modern medicine, in arriving a clinical diagnosis of the 
disease. 
 
1. Poriyaal arithal: (Inspection) Porigal are considered as the five senses of perception 
namely, 
1. Nose  
2. Tongue   
3. Eye    
4. Skin  
5. Ear 
ePu;fz khe;jj;jpy; Nehahspf;F fhZk; FwpFzq;fs;: 
 
nghwpahy; mwpjy; 
%f;F - %f;F ePu; gha;jy; 
eh - ,ay;G 
fz; - rpy Ntis fz; rptj;jy; 
fhJ - ,ay;G 
Njhy; - ,ay;G 
 
1. Pulanal arithal: (Palpation) 
Pulangal are functions of five senses.  
They are, 
1. Smell  
2. Taste 
3. Vision 
4. Sensation of Touch                                                                                                                                                                                                                                                                                                                                    
5. Hearing. 
 
Gydhy; mwpjy; 
CW - ,ay;G 
Xir - ,ay;G 
Xsp - ,ay;G 
Rit - ,dpg;Gr; Rit njupjy; 
ehw;wk; - %f;fpy; rsp rt;T jbg;GWjy; 
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Vinathal: (Interrogation) 
Vinathal is asking the information regarding the history of the disease, its clinical 
feature etc., from the patient or his close relatives who are taking care of him/her.  
 
tpdhTjy;: 
kUj;Jth; Nehahspaplk; tpdhTjy; %yk; Nehiaf; fzpf;f KbAk; 
Nehahspahy; Ngr Kbahj Neuj;jpy; mtd; Rw;wj;jhhplk; tpdhTjy; %yk; 
Nehiaf; fzpf;f KbAk;. rpj;j kUj;Jtj;jpd; Neha;fzpg;gpy; gpd;tUk; fhuzpfs; 
Kf;fpa gq;F tfpf;fpd;wd. 
 
Nehahspiar; rhh;e;jJ 
1. caph; jhJf;fs; (Kf;Fw;wk;) 
2. cly; jhJf;fs; (VO clw;fl;Lfs;) 
3. vz;tifj; Njh;T  
 
Nehahspiar; rhuhjJ 
4. nghOJ 
rpWnghOJ    - itfiw> tpbay;> vw;ghL> ez;gfy;> khiy> 
ahkk; 
ngUk;nghOJ  - fhh;> $jph;> Kd;gdp> gpd;gdp> ,sNtdpy;> 
KJNtdpy; 
  
    5. Itif epyq;fs; : FwpQ;rp> Ky;iy> kUjk;> nea;jy;> ghiy. 
 Nkw;$wpa fhuzpfspd; khWghLfis xd;Wld;      
 xd;W xg;gpl;L Neha; fzpf;fg;gLfpwJ. 
 
1. caph; jhJf;fs; (Kf;Fw;wk;) 
ePh; fzkhe;jj;jpy; Kf;Fw;w tpfw;gk; 
thjk;> gpj;jk;> fgk; Mfpa %d;W jhJf;fspy; rkr;rPH epiyapy; cz;lhFk; 
NtWghLfis Nehahf cw;gj;jpahfpwJ. 
 
(m)  „eLq;fpaNjhh; gpj;jkJ Nfhgq; nfhz;L 
 ey;ythAit gw;wp aOj;jpf; nfhs;Sk;” 
  -ghy thflk; 
 
Kjypy; gpj;jNjhlk; ghjpg;gile;J (jd;dpiy tsh;r;rp mile;J) gpd;G 
tspFw;wj;jpd; njhopiyAk; (Ntw;Wepiy tsh;r;rp mile;J) ghjpg;gjhf 
nfhs;syhk;. 
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,Nj fUj;ij „ke;jkyhJ thAtuhJ” -; vd;w Njud; Nrfug;gh ghlyhy; 
ke;jj;jpdhy; thA cz;lhFk; vd mwpayhk;. NkYk; khe;jk; (ke;jk;) vd;gJ 
gpj;jj;jpd; jd;dpiy tsh;r;rp Fzk; vd mwpaNtz;Lk;. 
  
(M)  „IaJ $bw; nwd;why;”                            -ghy thflk; 
,jd; nghUs; Iaf;Fw;wk; jd;dpiyapy; tsh;r;rp miljy; vd;gjhFk;.  
 
,Nj fUj;ij „fgj;jpidad;wp fhrRthrk; fhzhNj” - vd;w 
Njud;Nrfug;gh ghlyhy; Iaf;Fw;wj;jpd; jd;dpiy tsh;r;rpad;wp fzj;jpd; 
FwpFzkhd fhrk;> Rthrk; tuhJ vd mwpayhk;. moy; Fw;wk; jd;stpy; kpFe;J 
thAit gw;wp mOj;jpf; nfhs;Sk;. mjdhy; clypy; mjpfg;gl;l moy; 
jzptjw;F topapy;yhky; Foe;ijf;F mjpfkhf #L cz;lhfp cly; fdfdg;G 
Vw;gLfpd;wJ. 
 
capu; jhJf;fs;: 
ePu;fz khe;jj;jpy; thjj;jpd; epiy 
1. gpuhzd; : ghjpg;G( ,Uky;, Jk;ky; fhZjy; ) 
2. mghdd; : ghjpg;G (rpyNtis fopr;ry; fhzy;) 
3. tpahdd; : ghjpg;G (cly; Fd;Wjy;) 
4. cjhdd; : ghjpg;G (,Uky; fhZjy;) 
5. rkhdd; : ghjpg;G (grpapd;ik fhzy;) 
6. ehfd; : ,ay;G 
7. $u;kd; : ,ay;G 
8. fpUfud; : ghjpg;G (,Uky;, %f;fpy; ePu; gha;jy;) 
9. Njtjj;jd; : ,ay;G 
10. jdQ;rad; : - 
 
ePu;fz khe;jj;jpy; gpj;jj;jpd; epiy: 
1. mdw;gpj;jk; : ghjpg;G (grpapd;ik fhzy;) 
2. ,uQ;rfgpj;jk; : ghjpg;G (Kfk; ntSj;Jf; fhzy;) 
3. rhjfgpj;jk; : ghjpg;G (cly; Nrhu;T fhzy;) 
4. gpuhrfk; : ,ay;G 
5. MNyhrfk; : ,ay;G 
 
ePu;fz khe;jj;jpy; fgj;jpd; epiy: 
1. mtyk;gfk; : ,ay;G 
2. fpNyjfk; : ghjpg;G (nrupahik) 
3. Nghjfk; : ,ay;G 
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4. jw;gfk; : rpyNtis fz; rptj;jy; 
5. re;jPfk; : ,ay;G 
 
2. ePh; fzkhe;jj;jpy; cly;jhJf;fspd; epiy: 
cz;lcztpd; md;drhukhdJ Flypy; cwpQ;rg;gl;L clw; jhJf;fshd rhuk;> 
nre;ePh;> Cz;> nfhOg;G> vd;G> %is> Rf;fpyk; (m) RNuhzpjk; Nghd;wtw;iw 
Nghlzpf;fpd;wJ vd cly;jj;Jt E}y;fs; $Wfpd;wd. 
„je;jpL euk;g njy;yhe; jhq;fpNa A+izg; gw;wp 
 ce;jpL kpuj;jnky;yh kKnjd Tz;Z kd;Nw” 
     - guuhrNrfuk; - ghyNuhf epjhdk; ghly;: 269 
 
vd;w ghlyhy; fiz Neha; cly; jhJf;fis ghjpf;Fk; vd mwpayhk.; 
fizapy; cly; jhJf;fs; Nghlzpf;fg;gLtjpYk;> cUthf;fj;jpYk; rpukk; 
Vw;gLfpwJ vd;gjhy; Neha; jPtpuj;jpw;F Vw;g midj;J jhJf;fSk; (Rf;fpy> 
RNuhzpjk; cs;gl) thpirahf xd;wd;gpd; xd;whf ghjpg;gilAk; vd 
fUjg;gLfpwJ. Rf;fpyk;> RNuhzpjk; ,tw;iw Neubahf tpe;J> ehjk; vd;W 
nghUs; nfhs;shky;> cly; nry;fs; kw;Wk; cWg;Gfs; jd;idnahj;j cUtg; 
ngUf;fpw;F Kjyha; epw;Fk; cly; jhJ vd nghUs; nfhs;tJ rpwg;ghFk;.  
 
ePu;fz khe;jj;jpy; clw;fl;Lfspd; epiy: 
1. rhuk; : ghjpg;G (clw;Nrhu;T fhzy;) 
2. nre;ePu; : ghjpg;G (Kfk; ntSj;Jf;fhzy;) 
3. Cd; : ,ay;G 
4. nfhOg;G : ,ay;G 
5. vd;G : ,ay;G 
6. %is : ,ay;G 
7. Rf;fpyk;/RNuhdpjk; : - 
 
3.ePh; fzkhe;jj;jpy; vz;tifj; Njh;Tfs;: 
nghwp> Gyd;fshy; mwpjy;> tpdhjy; Nghd;witfspd; %yk; kUj;Jth; 
mwpe;jtw;iw vz;tifj; Njh;Tfs; %yk; cWjpgLj;j Ntz;Lk;. 
„ehb ];ghprk; eh epwk; nkhop tpop 
 kyk; %j;jpukpit kUj;JtuhAjk;”- Neha;ehly; Kjy; ghfk;        
‟Njba tpahjpf; nfy;yk; Njfj;jpy; ghpl;irAz;L 
 $bNa epw;Fnkl;L ghpl;irahq; $wf;NfsPh; 
 ehbNa njhl;lhw; Njfk; %j;jpuk; thh;j;ij fz;fs; ehf;F 
 ghbNa kyryq;fs; gy tz;zk; ghh;j;Jf; nfhs;Ns” 
        - rpj;j kUj;Jtkzpfs; 
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Nkw;$wpa ghlypd; %yk; ehb> ];ghprk;> eh> epwk;> nkhop> tpop> kyk;;> %j;jpuk; 
Mfpad kUj;Jthpd; MAjk; Nghd;wit vd mwpayhk;. 
 
(1) ehb 
vz;tifj; Njh;Tfspy; gpujhdkhdJ. gpzpapid ehbahywpe;J 
kUe;J}l;LjNy rpwe;jJ vd;W rpj;j kUj;Jtk; $Wfpd;wJ. Mdhy; Foe;ijfspy; 
ehbeil rhpahf Njhd;whJ vd;gij fPo;fz;l ghlyhy; mwpayhk;. 
 
 ‟nfhz;blNt faNuhfp fhrNuhfp 
 Fwpg;ghf rpw;wpd;gk; nra;j Ngh;fs; 
 mz;blNt jhpj;jpuh;fs; tpUj;jh; ghyh; 
 nfhz;blNt ,th;fspd; cWg;gpd; jhJ 
 $wNt KbahJ vth;f;Ff; fpl;Lk;.” 
                                    -Neha;ehly; Neha; Kjy;ehly; jpul;L 
 
vdpDk; fzj;jpy; gpj;jFw;wk; Kjd;ikahf ghjpj;J gpd; thj> fg Fw;wq;fSk; 
ghjpg;gjhy;> fPo;fz;l ehbeilahdJ Njh;thsuhy; ghpNrhjpj;J vOjg;gl;lJ. 
- gpj;jfgk; 
- gpj;jthjk; 
-  thjgpj;jk; 
 
(2).];ghprk;: 
 
Nehahspapid njhl;L ghh;j;jypd; %yk; czug;gLk; FwpFzq;fs; MFk.; 
ePh;fzkhe;jj;jpy; fPo;f;fhZk; FwpFzq;fs; mt;thW czug;gl;lJ. 
-tapWtyp;> Ruk;> cl;Ruk;. 
 
(3) eh 
 
Nehahshpd; ehf;fpid ghh;j;J czug;gLk; fzNehapd; FwpFzq;fshtd  
-nre;ePh;j;jhJ Fiwe;J fhZjiy> eh ntspwpl;L ,Uj;jyhy; mwpayhk;. 
 
(4) epwk;: 
ePh; fzkhe;jj;jpy; clw;fl;Lfs; td;ik Fiwe;Js;sij 
mwpaepwg;ghpNrhjid gad;gLk;. 
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 Njhypd; epwk;  -  ntspwpf;fhZjy; 
     fWj;Jf;fhZjy; 
 eh> fz;  -  ntspwpf;fhZjy; 
 
(5) nkhop: 
ePh; fzkhe;jj;jpy; Foe;ijfspy; fgk; mjpfhpf;Fk; fhuzj;jhy; Fuy;fk;ky; 
Njhd;wp jho;e;J NgRth;. 
 
(6) tpop: 
tpopr;Nrhjidapy;> fzNehapy; fPo;f;fhZk; FwpFzk; czug;gl;lJ. 
-fPopik ntspwpf;fhZjy; 
 
(7) kyk;: 
fzNeha; Foe;ijfspy;> tpdhjypd; %yk fPo;fz;l FwpFzq;fs;mwpayhk;. 
- fopr;ry; 
- kyr;rpf;fy; 
 
(8) %j;jpuk;: 
Foe;ijfspy; Ngjp ,Ue;jhy; clypd; ePh;j;Jtk; Fiwe;J ePh;;;; ;tuj;J 
Fiwe;J fhZk;. 
 
(9) ePh;f;Fwp: 
 “mUe;Jkhwp ujKk; mtpNuhjkha; 
m/fy; myh;jy; mfhyt+d; jtph;j;jow; 
Fw;wstUe;jp cwq;fp itfiw 
Mbf; fyrj; jhtpNa fhJnga; 
njhU K$h;j;jf; fiyf;Fl;gL ePhpd; 
epwf;Fwp nea;f;Fwp epUkpj;jy; flNd” 
-Neha; ehly; Neha; Kjy;ehly; gFjp-1 
 
tpsf;fk; 
ePu;f;Fwp ghu;f;Fk; Kjy; ehs; ,uT ed;F czT cz;Lcwq;f Ntz;Lk;. 
gpd; tpbaw;fhiy gbfghj;jpuj;jpy; ePupidg; gpbj;J mjd; ePu;Fwp kw;Wk; 
epwf;Fwpapid fz;lwpjy; Ntz;Lk;. 
 
“te;j ePh; fhpnail kzk; Eiu vQ;rnyd; 
 iwe;jpaYsit aiwFJ KiwNa” 
      - Neha; ehly; Kjy; ghfk; 
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ePhpy; epwk;> kzk;> Eiu> vil> vQ;ry;> Mfpatw;iw Nehf;f Ntz;Lk;. 
 
nea;f;Fwp: 
“epwf;Fwpf; Fiuj;j epUkhz ePhpw; 
rpwf;f ntz;nza;Nahh; rpWJsp eLtpLj; 
njd;Wwj; jpwe;njhyp Nahfh jike;jjp 
dpd;w jptiy Nghk; newptpopawpAk; 
rpWePupy; ey;nyz;nz;a; tpl;L ghu;g;gJ‟ 
-Neha; ehly; Neha; Kjy;ehly;gFjp-1. 
 
Foe;ijfspd; ehbeil rhpahf fzpg;gjpy; rpukk; cs;sjhy;> nea;f;Fwp 
ghpNrhjid %yk; Nehahsh; vf;Fw;wj;jhy; ghjpf;fg;gl;Ls;shh; vd;gjid 
fzpf;fyhk;.fzNehahspapd; rpWePiu Nrhjid tl;bypy; Cw;wp xsp kpFe;j 
,lj;jpy; ePhpd; miyapy;yhj NghJ ey;nyz;nzaj;;Jsp tp;l;L ghh;f;fg;gl;lJ. 
rpyhpy; Mop Nghy; (Nkhjpuk;) gutpAk;> rpyhpy; Kj;JNghy; epd;Wk; fhzg;gl;lJ. 
„muntd ePz;bd; thjk; 
 MopNghw; gutpd; gpj;;jk; 
 Kj;njhj;J epw;fpd; nkhoptnjd; fgNk”- Neha; ehly; Kjy; ghfk; 
kUj;Jtk; 
1. Ntw;Wepiy tsh;r;rpaile;j gpj;jj;jpid jd;dpiyg;gLj;j Ntz;Lk; 
2. jd;dpiy tsh;r;rpaile;j Iaj;jpid rkg;gLj;j Ntz;Lk; 
3. gpj;jFw;wj;jhy; ghjpg;gile;Js;s thjj;jpidAk; rhpg;gLj;j Ntz;Lk;. 
4. td;ik ,oe;j clw;fl;Lfis td;ik milar;nra;Ak; tifapy; 
kUe;jspf;f Ntz;Lk;. 
 
Keeping in mind the need for bringing out an effective therapy for Neerkana 
manthamfrom Siddha system of Medicine, the author has taken this clinical study with 
KARAI RASAYANAM. The dosage of medicines are- 3 to 7 years (4 to 5ml b.d) 
 
Line of Treatment: 
 Siddha treatment is not only for complete healing but also prevention and 
rejuvenation. Saint Thiruvalluvar says about physician‟s duty, study the disease, study the 
cause, treat subsiding way and do what is proper and effect. 
 
„Neha; ehb Neha; Kjy; ehb mJ jzpf;Fk; 
 tha;ehb tha;g;gr; nray;. 
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 „cw;whd sTk; gpzpasTq; fhyKq; 
 fw;whd; fUjpr; nray;.” 
    - jpUf;Fws; 
So it is essential to know the disease, the etiology, the nature of patients, severity 
of the illness, the seasons and the time of occurrence.Line of treatment is as follows. 
1. Kaappu (Prevention) 
2. Neekkam (Treatment) 
3. Niraivu (Restoration) 
 
 
1.Kaappu (Prevention):  
Prevention and cure of the diseases are the basic principle of any medical system, 
but prevention is the main aim of Siddha system. Siddhars have described general 
preventive measures and special measures. (Which are applicable to diseases of certain 
organs) and especially in Balavagadam, the preventive measures are explained in detail. 
Prevention of the disease of the child starts from the conception and goes on as the child 
grows up in intra uterine life and after delivery.  Siddhars have dealt elaborately with the 
diet of pregnant women, her habit, the medicine to be taken in every month, her 
psychological conditions, etc. 
 
2. Neekam: (Treatment) 
The aim of treatment is based on,To bring the three thodams into normal 
equilibrium state, emetics and purgatives are given. But considering physical condition of 
the children administration of purgatives and emetics is excluded from line of 
treatment.To treat the patient according to the symptoms by internal medicine “Karai 
rasayanam” 
 
3.  Niraivu: (Restoration) 
Reassurance of disease recovery was given to all patients.All the patients are 
advised to follow the life style that provides a disease free life.  
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Pathiyam (Diet): 
During the course of treatment, the drug is administered to the patients according 
to the nature of disease and the patients were advised to follow certain restrictions 
regarding diet and physical activities. 
  „gj;jpaj;jpdhNy gyDz;lhFk; kUe;J 
 gj;jpaq;fs; Nghdhy; gyd; NghFk; - gj;jpaj;jpy;  
 gj;jpaNk ntw;wpjUk; gz;bjHf;F Mjypdhy; 
gj;jpaNk cj;jpnad;W ghH”  (-Nj.nt) 
 
The patient with Neerkana mantham advised to avoid cool drinks, cold water and 
exposure to chill weather and allergens (dust and odours).During the course of treatment 
according to the drug administered to the patients and nature of the disease, the patients 
were advised to follow certain precautions regarding diet and physical activities. This 
type of medical advice in Siddha system of medicine is termed as Pathiyam.  
 
SIDDHARS ADVICE REGARDING THE DIET REGIMEN FOR KABA 
PATIENTS IS EXPLAINED BELOW: 
                  „fj;jhp Nga;g;Gly; tiu apUghfy; gUq;fsh fz;lfhhp 
  mj;jpf; fha;fSk; tUf;ifkhgaw;iw fiuahy; gPHf;fUk; - gpQ;RNtH 
nkha;j;j R+uzq; fjypj; jz;Lfisg; g+Ksq;fp KUf;fUk;Gk; 
  mj;jpg; g+rpdpf; fhaUs;sp ts;spAq; fgj;NjhHf; fhzkhNk” 
Ntis kzj;jf;fhsp nkd; rPij rf;utHj;jp 
 gPis triy Rf;F ngz;Rzq;fs; - Ntisapiy 
 nre;jspH fisf; fPiu nra;tH fgNjfH epjk;  
 te;jdpAzj;jhd; kfpo;e;J” 
-gjhHj;j Fz rpe;jhkzp                     
 
nghUs; : 
   fj;jhp> Ngag;Gly;> ghfy;> fsh> mj;jpf;fha;> gPHf;;fqfha;> fjypj; jz;L> 
Ks;sq;fp> fUk;G> g+rpdpf;fha> cs;sp> ,itfis jtpu;f;fTk;. 
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3.REVIEW OF LITERATURE 
3.2MODERN ASPECT 
 
ACUTE NASO PHARYNGITIS (common cold) 
Upper respiratory tract infections are those primarily affecting the respiratory tract 
above the level larynx. Acute naso pharyngitis is the most common infections of children. 
In children, this disease is more extensive than in adults, often involving the para nasal 
sinuses and middle ear as well as the naso pharynx. 
 
 
 
Fig:1 Anatomy of Upper respiratory tract 
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ETIOLOGY: 
The illness is caused by more than 200 serologically different viruses and bacteria. 
  
EPIDEMIOLOGY: 
This infection occurs throughout the year but peak of occurrence in rainy and 
autumn.Children have an average of five to eight infections a year.  
 
The frequency of acute nasopharyngitis varies directly with the number of 
exposures and in nursery schools and day care centers.Susceptibility may be increased by 
poor nutrition, purulent complications are increased by malnutrition The common cold is 
an acute respiratory tract infection (ARTI) characterized by mild coryzal symptoms, 
rhinorrhea, nasal obstruction, and sneezing. Although the list of agents that cause the 
common cold is large, 66-75% of cases are due to 200 antigenically distinct viruses from 
8 different genera. RVs are the most common of these (25-80% of cases), followed by 
coronaviruses (10-20%),influenza viruses (10-15%), and adenoviruses (5%).Although the 
incidence of ARTI cannot be clearly defined, because of seasonal and locational 
variability, it is estimated to range from 3-6 cases per person per year in thecountry. 
Children younger than 1 year have experienced an average of 6-8 episodes of ARTI. This 
figure decreases to 3-4 episodes per year by adulthood. 
 
AGE-RELATED DIFFERENCES IN PRESENTATION ARE AS 
FOLLOWS: 
Infants and preschoolers – Fever more likely, often 38-39°C 
Infants and toddlers – May display only nasal discharge 
School-aged  children - Usually complain of nasal congestion, cough, and runny 
nose 
 
RHINO VIRUS 
Rhinoviruses (RVs) are more than 100 different subtypes exist in 3 major groups, 
categorized according to receptor specificity.RV infections are chiefly limited to the 
upper respiratory tract but may cause otitis media and sinusitis; they may also 
exacerbate asthma, cystic fibrosis, chronic bronchitis, and serious lower respiratory tract 
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illness in infants, elderly persons, and immunocompromised persons. Although infections 
occur year-round, the incidence is highest in the fall and the spring. Of persons exposed 
to the virus, 70-80% has symptomatic disease. Most cases are mild and self-limited. 
 
Highly contagious behavior includes nose blowing, sneezing, and physically 
transferring infected secretions onto environmental surfaces or paper tissue. Contrary to 
popular belief, behaviors such as kissing, talking, coughing, or even drooling do not 
contribute substantially to the spread of disease. 
 
Infection rates approximate 50% within the household and range from 0% to 50% 
within schools, indicating that transmission requires long-term contact with infected 
individuals. Brief exposures to others in places such as movie theaters, shopping malls, 
friends‟ houses, or doctors‟ offices are associated with a low risk of transmission. 
Because children produce antibodies to fewer serotypes, those who attend school are the 
most common. 
 
PATHOPHYSIOLOGY 
 
URIs involve direct invasion of the mucosa lining the upper airway. Person-to-
person spread of viruses accounts for most URIs. Patients with bacterial infections may 
present in similar fashion, or they may present with a superinfection of a viral URI. 
Inoculation by bacteria or viruses begins when secretions are transferred by touching a 
hand exposed to pathogens to the nose or mouth or by directly inhaling respiratory 
droplets from an infected person who is coughing or sneezing. After inoculation, viruses 
and bacteria encounter several barriers, including physical, mechanical, humoral, and 
cellular immune defenses. Hair lining the nose filters and traps some pathogens. Mucus 
coats much of the upper respiratory tract, trapping potential invaders. The angle resulting 
from the junction of the posterior nose to the pharynx causes large particles to impinge on 
the back of the throat. Ciliated cells lower in the respiratory tract trap and transport 
pathogens up to the pharynx from there they are swallowed into the stomach.  
 
Adenoids and tonsils contain immune cells that respond to pathogens. Humoral 
immunity (immunoglobulin A) and cellular immunity act to reduce infections throughout 
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the entire respiratory tract. Resident and recruited macrophages, monocytes, neutrophils 
and eosinophils coordinate to engulf and destroy invaders. A host of inflammatory 
cytokines mediates the immune response to invading pathogens. Normal nasopharyngeal 
flora, including various staphylococcal and streptococcal species, help defend against 
potential pathogens. Patients with suboptimal humoral and phagocytic immune function 
are at increased risk for contracting a URI, and they are at increased risk for a severe or 
prolonged course of disease.Most symptoms of URIs, including local swelling, erythema, 
edema, secretions and fever, result from the inflammatory response of the immune system 
to invading pathogens and from toxins produced by pathogens. 
  
An initial nasopharyngeal infection may spread to adjacent structures, resulting in 
sinusitis, otitis media, epiglottitis, laryngitis, tracheobronchitis, and pneumonia. 
Inflammatory narrowing at the level of the epiglottis and larynx may result in a dangerous 
compromise of airflow, especially in children, in whom a small reduction in the luminal 
diameter of the subglottic larynx and trachea may be critical. Beyond childhood, 
laryngotracheal inflammation may also pose serious threats to individuals with congenital 
or acquired subglottic stenosis.  
 
CLINICAL MANIFESTATIONS 
Manifestations of RV infection typically appear after an incubation period of 12-
72 hours and last 7-11 days, but may persist for longer. 
Signs and symptoms include the following: 
 Nasal dryness or irritation - May be first symptom 
 Sore throat or throat irritation – Common and bothersome initial symptom 
 Nasal discharge, nasal congestion, and sneezing – Intensify over 2-3 days 
 Headache 
 Cough (30% of infected individuals) 
 Hoarseness (20%) 
 Posttussive vomiting 
 Irritability or restlessness 
 Anorexia 
 Ingestion of infected secretion may cause diarrhoea and abdominal pain. 
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PHYSICAL EXAMINATION FINDINGS 
 Typically less severe than the symptoms reported by the patients. 
 Fever uncommon, though temperatures of 38-39°C are possible in younger 
children. 
 A red nose with a profuse, dripping nasal discharge may be present. 
 Nasal discharge can be clear and watery or mucopurulent (yellow or green). 
 The nasal mucous membranes have a glistening, glassy appearance. 
 The pharynx typically appears normal, without any erythema, exudate, or 
ulceration. 
 Mildly enlarged, nontender cervical lymph nodes are present. 
 
SIGNS SUGGESTIVE OF COMPLICATIONS 
 Exudative tonsillitis 
 Tender anterior cervical lymphadenopathy 
 Otalgia, otorrhoea, hearing loss 
 Tenderness over sinus area 
 Dyspnoea and Tachypnoea, pleuritic chest pain 
 Neck stiffness 
 
SYMPTOMS AND SIGNS SUGGESTIVE OF SERIOUS ILLNESS: 
 High fever, fever > 72 hours, delayed onset of fever 
 Severe headache 
 Upper airway obstruction – stridor 
 Lower airway – dyspnoea, tachypnoea 
 
RISK FACTORS 
Factors that increase the risk and severity of RV infection include the following: 
 Smoking increases the risk of respiratory infection by approximately 50% 
 Very young or old individuals are at greater risk, possibly because of decreased 
immunity 
 Exposure to infected contacts increases the risk of infection 
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 Touching the conjunctivae or the nose with contaminated fingers or 
objects increases the risk of infection 
 Crowding leads to increased transmission (eg, day care settings) 
 Men may have a slightly higher risk, but the increase is probably     
      insignificant 
 Breastfeeding has little effect on the incidence of the common cold. 
 Underlying chronic medical conditions, including anatomic, metabolic,    
     genetic, and immunologic disorders (eg, tracheoesophageal fistula,  
      congenital heart disease, cystic fibrosis, or immunodeficiency) increase the  
     risk and severity of infection 
 
COMPLICATIONS: 
 Laryngitis.  
 Mastoiditis.  
 Peritonsillarcelulitis.. .   
 Otitis media 
 Sinusitis 
 Chronic bronchitis 
 Exacerbations of reactive airway disease 
 
DIAGNOSTIC ASPECT 
  If findings from a thorough history and physical examination are consistent with a 
viral etiology and no complications are noted, an aggressive workup is rarely necessary 
 
LABORATORYDIAGNOSTIC TESTS FOR UPPER RESPIRATORY 
TRACT INFECTIONS 
 Complete blood count 
 Haemoglobin 
 Total count and differential count 
 Erythrocyte sedimentation rate 
 Absolute eosinophil count (AEC) 
 PNS 
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 Radiograph of paranasal sinuses 
 Temperature 
 Gramstain for pathogens 
 IgE levels 
 Histamine levels 
 
RV infections are predominantly mild and self-limited; thus, treatment is generally 
focused on symptomatic relief and prevention of person-to-person spread and 
complications. 
 
DIFFERENTIAL DIAGNOSIS: 
 1. ALLERGIC RHINITIS: 
 It is not accompanied by fever. 
 Its nasal discharge does not usually become purulent 
 It is usually combined with persistent sneezing and itching of the eyes and 
nose. 
 Nasal smears often contain many eosinophils rather than 
polymorphonuclear  leucocytes associated with infection. 
 
2. FOREIGN BODY: 
Unilateral serosanguineous (or) purulent discharge from the nose indicates history 
of any nasal ingestion or presence of foreign body. 
 
3.ACUTE BRONCHITIS: 
It is not accompanied with wheezing 
There is no chest tightness , dyspnea 
 
STATISTICAL ANALYSIS 
Common colds are most frequent from September to April in temperate climates. 
RV infections, which are present throughout the year, account for the initial increase in 
cold incidence during the fall (causing as many as 80% of colds in this period) and for a 
second incidence peak at the end of spring. Colds that occur from October through March 
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are caused by the successive appearance of numerous viruses (see the image below). 
Adenovirus infections occur at a constant rate throughout the season. 
 
Seasonal variations in frequency of selected upper respiratory tract infection 
pathogens. PIV = parainfluenza virus; RSV = respiratory syncytial virus; MPV = 
metapneumovirus; Group A Strept = group A streptococcus. 
 
The incidence of the common cold is highest in preschool- and elementary 
school–aged children. An average of 3-8 colds per year is observed in this age group, and 
the incidence is even higher in children who attend daycare and preschool. Because of the 
numerous viral agents involved and the multiple serotypes that several of these agents 
(especially RV) have, it is not unusual for younger children having new colds every 
month during the winter. Adults and adolescents typically have 2-4 colds per year. 
 
International statistics 
Internationally, RV is a significant cause of respiratory tract infectionas well as a 
minor cause of bronchiolitis.
 
RVs have been found in all countries, even in remote areas 
such as the Kaluhi Islands and the Amazon. In Brazil, RVs reportedly cause 46% of 
ARTIs. A seasonal increase in incidence during the winter months is observed worldwide. 
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Age-related demographics 
Because antibodies to viral serotypes develop over time, the incidence of RV 
infection is highest in infants and young children and falls as children approach 
adulthood. Young children are more likely to have the frequent, close, personal contact 
necessary to transmit RV; they commonly pass the infection to family members after 
acquiring the virus in nurseries, daycare facilities, and schools. Children may also be 
more contagious by virtue of having higher virus concentrations in secretions and longer 
duration of viral shedding. 
 
Sex-related demographics 
Some reports indicate a male predominance of infection in children younger than 
3 years, which switches to a female predominance in children older than 3 years. In 
adults, no difference in rates of infection between men and women is apparent. 
 
Race-related demographics 
No differences among different races with respect to susceptibility to RV infection 
or disease course have been described. In general, Native Americans and Eskimos are 
more likely to develop the common cold and appear to have higher rates of complications 
such as otitis media. These findings may be explained as much by environmental 
conditions (eg, poverty and overcrowding) as by ethnicity. 
 
PROGNOSIS 
The prognosis for RV infection is excellent. The most common manifestation of 
RV infection, the common cold, is mild and self-limited. Complete recovery is usually 
observed within 7 days for adolescents and adults and within 10-14 days for children. 
Occasionally, a child‟s cough and congestion linger for 2-3 weeks.Although rarely 
associated with fatal disease, rhinoviruses are associated with significant morbidity. 
ARTIs, predominantly RV infections, are estimated to cause 30-50% of time lost from 
work by adults and 60-80% of time lost from school by children. Severe respiratory 
disease, including bronchiolitis, asthmaexacerbations, and pneumonia , can occur, 
particularly in infants and young children. Preterm infants are also at high risk for severe 
RV infection.RV is a predominant pathogen in lower respiratory tract infections (LRTI) 
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in very low birth weight infants
 
and shares predominance in LRTI among young infants 
with respiratory syncytial virus (RSV) RVs may also be involved in LRTIs in elderly 
persons, persons with cystic fibrosis, and immunosuppressed patients. The true impact of 
LRTI is not clear. Recovery of RV in these patients may be a marker of an underlying 
disease process or a precursor to a bacterial infection. 
 
DIET: 
Fluid intake: Increased fluids are warranted to replace insensible losses and 
reduced oral intake.Probiotics- Antibiotics may affect  the gastrointestinal flora, and some 
foods may not be as digestible for days or weeks after antibiotics are used. Consumption 
of yogurt containing active cultures has been advocated as an aid to restoring normal flora 
after antibiotic therapy.  
Country Chicken soup or mutton soup  increases the clearance of nasal mucous. 
Drink- (water, fruit juice, tea, clear soup broths and non-caffeinated carbonated 
beverages). 
Add  pepper powder,turmeric powder,ginger,cardamomum,garlic in food. 
Avoid– refrigerated items,white sugar,bakery products,junk foods. 
 
TREATMENT  
 Anti tussive 
 Antibiotics 
 Anti-virals 
 Anti pyretic 
 De- congesant 
 Anti – histamine 
 
PREVENTION 
  Wash the hands frequently, especially after touching public surfaces like 
doorknobs. 
  Frequently wash toys, pacifiers, and other items that children tend to put in their 
mouths. 
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  Cover your mouth and nose when coughing or sneezing, and teach your children 
to do the same. 
Limiting the child‟s contact with people who may be sick, especially if your child 
is very young or especially at risk for getting sick. 
  Special attention should be paid to these infection-control methods in situations 
where children are in large groups, such as preschools and day-care centers. 
 Practicing good hygiene is very important. As the foods rich in simple sugars 
increases the osmotic load they should be avoided to children. 
Rehydration therapy for the replenishment of water and electrolytes lost in stools 
should be given for children. 
Intake of highly nutritious diet for increasing immunity and decreased 
suspectibility of infections in children. 
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3.REVIEW OF LITERATURE 
3.3DRUG REVIEW 
 
SCIENTIFIC AND SIDDHA PHILOSOPHICAL REVIEW OF TRIAL 
DRUG KARAI RASAYANAM 
 
fhiu urhazk; 
“fhiu ew;fdpapd; rhW 
   fUk;gpdpw; gQ;rjhiu 
XnuhU tiff;F ehop 
  clNd ehdhop Mg;ghy; 
NruNt tpl;L ghfha;  
   jpus nea; Aof;F tpl;L 
rhu ehnshpj;J cl;nfhs;s 
   rfy khfdKk; NghNk….” 
 
Nruk; ruf;Ffs; : 
  1. fhiu gok; 
  2. gRk;ghy; 
  3. gRnea; 
  4. fUk;G rh;f;fiu 
 
fhiu gok; 
Rit    : Jth;g;G ,dpg;G 
jd;ik   : jl;gk; 
gphpT    : ,dpg;G 
 
Fzk;: 
“FUjpg;Nghf;ifAk; fopr;riyAk; ePf;Fk; 
rPjf;fLg;Gk; nrwpe;jtpujf; fLg;Gk; 
XJkjprhuKk;Ngh Kz;ikNa – NkhJfly; 
 ePiug; gUFKfp Ndusf kpd;nfhbNa 
fhiu goj;jph;f;F fhz;” 
    -mfj;jpah; Fzthflk; 
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fhiuia Gspapl;L rikj;J cz;z uj;jf;fLg;G ePq;Fk;. goj;ij cilj;J 
tpiuia ePf;fp cyh;j;jp FbePhpl;L jpdk; ,UNtis Fbj;Jtu fopr;ry; mjprhuk; 
,itfs; NghFk;. 
 
CANTHIUM PARVIFLORUM 
PLANT DESCRIPTION  
Kingdom: Plantae  
Divison: Magnoliophyta  
Class: Magnoliopsida  
Clade: Angiosperms  
Order: Gentianales  
Family: Rubiaceae  
Subfamily: Ixoroideae  
Genus: Canthium  
Species: parviflorum 
 
REGIONAL AND OTHER NAMES 
English  : wildjessamine  
Kanada :  Balasu, Ganduk-koral, karee 
Malayalam : kara, kandangari, Niruri, kirma, kabdar 
Tamil  : karai 
 
HABIT AND HABITAT 
A rigid shrub or a small tree, occurring through out the deccan peninsular from 
Gujarat to maharastra southwards and in bihar and orrisa. 
 
PHYTO CHEMICAL COMPOUNDS 
Phytochemicals  
The secondary metabolites, especially the bioactive compounds present in the 
plants, provided the basis for several sophisticated traditional medicine systems like 
Ayurveda, Unani, and Folk. Phytomedicines such as aspirin, vincristine, vinblastine, 
cocaine, digitoxin, quinine, and morphine are still in used to treat or prevent various 
disorders (Sahoo et al., 2010). 
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Phyto-chemical analysis of Canthium parviflorum plant extracts revealed the 
presence of various bio-chemical compounds such asflavonoids, glycosides, alkaloids, 
saponins andterpenoids. 
Since terpenoids and flavonoids have remarkable anti-inflammatory activity, our 
present work aims at evaluating the in-vitro anti-inflammatory activity of Canthium 
parviflorum by protein denaturation method. 
  Different parts of Canthium parviflorum, have been used traditionally for the 
treatment of variety of diseases including anaemia, toothache, cough and as a 
hypoglycemic agent. Roots and leaves were used to reduce swellings in inflammation. 
The isolation of 
 taraxerol, sakuranetin-4'-Oglycoside 
 d-mannitol, petunidin 
 long chain ester from the thorns, 
 β-sitosterol, long chain acids and alcohols 
from the leaves of Canthium parviflorum Lam. is being reported for the first time.  
 
PHARMACOLOGICAL SCREENING 
 A large number of medicinal plants still remain to be investigated for their 
possible pharmacological values. The chemical constituents of plant may help as 
cofactors for already available biologically active compounds (Nahrstedt et al., 2010).  
International Standard Serial Number (ISSN): 2249-6807 79 Full Text Available On 
www.ijipls.com Kala et al., 2014 reported though the callus extract of Canthium 
parviflorum has callus extracts do not contain potent antioxidant, α-glucosidase, 
hypocholesteromic and tyrosinase inhibition activities.  
 
In addition to this, the Canthium plant extracts also showed anti-inflammatory 
activity and cytotoxic activity also. Canthium parviflorum chloroform callus extract has 
shown remarkable cytotoxicity. It is likely that anti-cancer activity of this plant extract 
might be attributed to anti-oxidant activity. 
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A REVIEW ON PHYTOCHEMICAL AND PHARMACOLOGICAL 
SIGNIFICANCE OF CANTHIUM PARVIFLORUM LAM 
ACTIVE CONSTITUENTS IN CANTHIUM PARVIFLORUM 
Ethanolic extracts of Canthium parviflorum reported that the 22 active 
constituents present in the leaf which are later confirmed by GC-MS analysisBiphenyl, 2-
Methyl-4-heptanone, Di-Isodectyl Phthalate, 1,2,4,5-Tetroxane, 3,3,6.6-Tetrapheny,-3-
Oxo-Alapha,-Ionol, Methyl 7-hydroxy-2-methyl-3,5-octadienoate, 4-(2-Hydroxy-2,6,6-
Methyl cis-11,14,17-Icosatrienoate, Trimethyl cyclohexyl)-3-buten-2-one, n-
Hexadecanoic acid, E-11-Hexadecanoic acid, Ethyl ester, Ethyl Hexadecanoate, Phytol, 
Ethyl (9Z,12Z)-9,12-Octadecanoate, Ethyl Linolenate, 1-Hexadecanol, 2-Phenoxyl-2-
phenylpropanic acid, All-trans-squalene,  Methyl Linolenate, Gamma-Tocopherol, 
DEPH; 1,2-Benzenedicarboxylicacid, bis (2-hylhexyl) ester, Stigmasterol and Gamma-
stigmasterol . Based on the phytochemical results, it is concluded that Canthium 
parviflorum is most economically valuable plant. 
 
ANTIOXIDANT ACTIVITY  
The major goals of antioxidant treatments are to reduce oxidative stress by 
preventing or delaying the progression or reversing the complications of the disease. 
Medicinal plants often contain substantial amounts of antioxidants such as polyphenols, 
flavonoids, anthocyanins, and tannins. 
 
Antioxidant and diuretic activity were exhibited by extracts of Canthium 
parviflorum leaves. More antioxidant activity exhibited by the leaf extract of Canthium 
parviflorum .This anti-oxidant activity might be attributed due to the presence of 
phytochemicals such as flavonoids and bioflavonoids .Palvai et al. (2014) reported that 
the methanolic leaf extract of Canthium parviflorum exhibited good antioxidant activity. 
Prabhu et al., (2014). Reported that the Canthium parviflorum leaf extracts showed Potent 
of antioxidant and anti-arthritis activity  
 
Previously reports on methanolic fruits extract of Canthium parviflorum showed 
more antioxidant properties Ravichandra et al. (2014) reported that the bark extract of 
Canthium parviflorum exhibits free radical scavenging activity.  
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ANTIMICROBIAL ACTIVITY  
 
Canthium parviflorum leaf callus extracts exhibited potent antibacterial activity 
against both gram positive and negative bacteria, exactly the chloroform and methanol 
extracts showed high zone of inhibition and also showed high potent activity against few 
fungal species. (Kala et al., 2015) Based on the previous reports, results indicated the 
callus extracts of Canthium parviflorum has potent antibiotic compounds which need to 
be isolated, characterized and screened. 
 
ANTI-INFLAMMATORY ACTIVITY  
Due to the fast growing interest in the anti-inflammatory activity of medicinal 
plants by pharmaceutical companies and scientific research on the discovery of novel 
anti-inflammatory compounds, medicinal plants could potentially serve as leads in the 
production of new drugs for treating pain-related ailments with reduced or no side-effects.  
Canthium parviflorum leaves showed significant anti-inflammatory activity in in vitro 
methods tested by protein denaturation method. Denaturation of proteins is a well-
documented cause of inflammation and rheumatoid arthritis and the terpenoids and 
flavonoids showed remarkable anti-inflammatory activity. 
 
ANTIBACTERIAL ACTIVITY 
 P. Sathiya Priya et al,.(2009) was reported that the methanol extract of Ruta 
chalapensis (L), Quercus infectoria (Oliver) and Canthium parviflorum (Lam) against 
Staphylococcus aureus, Pseudomonas Sasmal et al _ aeruginosa, Enterococcus faecalis, 
Klebsiella pneumonia and Proteus mirabilisshowed significant zone of inhibition. 
 
ANTI PYRETIC AND ANTI DIARRHOEAL ACTION 
Ethno botanical study of medicinal plants of Sri Pancha Narasimha Swamy and 
Sri Matsyagiri Narasimha Swamy 
Canthium parviflorum L Thunb Balusu Rubiaceae  
      Used for the management of   fever, dysentery, hence it may be concluded that it has 
Anti – pyretic action and anti – diarrhoeal action. 
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ETHNO-MEDICINAL USES (RESPIRATORY INFECTIONS AND GI 
TRACT) 
Canthium parviflorum (Rubiaceae), a medicinal plant, has been widely used in 
Ayurvedha in conditions of kapha, diarrhea, strangury, fever, leucorrhoea, intestinal 
worms, and general debility. This plant has been traditionally known to treat snakebite in 
some villages of Shimoga district in Karnataka, India and to possess wound-healing 
property. The present study focused on determining the antioxidant ability of solvent 
extracts of C. parviflorum.  
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COW‟S MILK 
Ayub et al. (2007) described that milk is the best and cheapest source of nutrition 
and an article of daily diet, easily accepted and used by all the age groups in the mankind. 
Milk is a highly nutritious food, which is rich in several nutrients like calcium, potassium, 
vitamins and protein. Chirlaque ( 2011) stated that people have been using cow„s milk 
since 6,000-8,000 B.C. Since 14th century it has gained immense popularity as one of the 
healthiest foods.  
Milk meets the basic requirements of the body. It is highly beneficial in the 
growth and development of bones. It is also helpful in fighting against diseases like 
Respiratory illness, gout, kidney stones, breast cancer, rheumatoid arthritis, migraine 
headaches and others. Considering the innumerable health benefits of cow„s milk, 
knowing about its nutritional value will be highly helpful (Pandey and Voskuil 2011). 
 
ANABOLIC EFFECT OF COW MILK 
Cow's milk contains protein, which supports muscle growth and repair.Cow's milk 
is a rich source of high-quality protein (containing all of the essential amino acids), and 
whole milk is also a rich source of energy in the form of saturated fat, which can prevent 
muscle mass being used for energy. Protein found in dairy can support muscle growth and 
repair. According to Today's Dietitian, a recent analysis of over 20 clinical trials 
suggested that an increased milk intake can boost muscle mass and strength during 
resistance exercise in both younger and older adults. 
 
SOME IMPORTANT NUTRIENTS THAT ALL MILK PROVIDES INCLUDE: 
CALCIUM: (ENHANCES BODY STRENGTH ) 
Dairy products like milk are one of the richest dietary sources of calcium. Calcium 
has many functions in the body but its primary job is the development and maintenance of 
healthy bones and teeth. 
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Calcium is also important for blood clotting and wound healing, maintaining 
normal blood pressure, and muscle contractions including heartbeat. It is important to try 
to pair calcium-rich foods with sources of magnesium and vitamin D, as vitamin D 
supports calcium absorption in the small intestine and magnesium helps the body 
incorporate calcium into the bones. 
A cup of skim milk contains around 306 milligrams of calcium, with around 32% 
of this calcium thought to be absorbed.  
CHOLINE: ( ANTI INFLAMMATORY ACTION ) 
  Milk is also a rich source of choline; an important nutrient found to support sleep, 
muscle movement, learning and memory. Choline helps to maintain the structure of 
cellular membranes, aids in the transmission of nerve impulses, assists in the absorption 
of fat and can lessen chronic inflammation. 
 
POTASSIUM: ( IMPROVES FATIGUE) 
  An optimal intake of potassium is associated with a reduced risk of stroke, heart 
disease, high blood pressure, protection against loss of muscle mass, preservation of bone 
mineral density and reduction in the formationof kidney stones. A high potassium intake 
is associated with a 20% decreased risk of dying from all causes.
 
 The recommended daily intake of potassium for all adults is 4,700 mg per day.
 
A cup of cow's milk contains around 366 mg of potassium (slightly more than in most soy 
milk beverages), although the unpleasant digestive effects of lactose intolerance, such 
as diarrhea, can lead to potassium depletion. 
 
VITAMIN D (FORTIFIED):  (IMMUNE BOOSTER ) 
  Vitamin D is not naturally present in cow's milk, but may be added alongside 
other nutrients to fortify cow's milk as well as soy milk, etc. Vitamin D is important for 
bone health, aiding in the formation, growth, and repair of bones. This nutrient also plays 
an important role in calcium absorption and immune function.  
Milk is also fortified with numerous vitamins, including vitamins A and D, and 
may contain small amounts of vitamin B2 (riboflavin), vitamin B6 (around 0.1mg per 
cup) and vitamin B-12, as well as magnesium and phosphorus. Some of these vitamins 
(especially A and riboflavin) are destroyed by exposure to light, meaning that nutrient 
levels are low in milk stored in transparent containers. 
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LACTOFERRIN (LF): (ANTI MICROBIAL ACTION ) 
Is an iron binding glycoprotein that is present in several mucosal secretions. Many 
biological functions have  been  ascribed to LF. One of the functions of LF is the 
transport of metals, but LF is also an important component of the non-specific immune 
system, since LF has antimicrobial properties against bacteria, fungi and several viruses. 
This review gives an overview of the present knowledge about the antiviral activities and, 
when possible, the antiviral modes of action of this protein. Lactoferrin displays antiviral 
activity against both DNA- and RNA-viruses, including rotavirus, respiratory syncytial 
virus, herpes viruses and HIV. The antiviral effect of LF lies in the early phase of 
infection. Lactoferrin prevents entry of virus in the host cell, either by blocking cellular 
receptors, or by direct binding to the virus particles. 
 
CLA (CONJUGATED LINOLEIC ACID):   (ANTI INFLAMMATORY ACTION ) 
Is a type of fat associated with a wide variety of health benefits, including immune 
and inflammatory system support, improved bone mass, improved blood sugar regulation, 
reduced body fat, reduced risk of heart attack, and maintenance of lean body mass.  
According to recent studies, you'll find yourself getting at least 75 milligrams of 
CLA from an 8-ounce serving of grass-fed cow's milk.  
About 6-7% of this saturated fat is "short-chain" saturated fat and it can function 
as a "probiotic" that supports the health of friendly bacteria in the intestine. 
 
ANTIBACTERIAL AND IMMUNOSTIMULATING CASEIN 
DERIVED SUBSTANCES FROM MILK: CASECIDIN, ISRACIDIN PEPTIDES 
Apart from immunoglobulin A and G antibodies and plasma cells, milk also 
contains antibiotic/host protective peptides that are of value not only for maintenance of 
its nutritional integrity but also for protection of the newborn and, possibly, protection of 
the lactating mother. Among the first such peptides identified was casecidin; following 
chymosin digestion of casein at pH 6 or 7, casecidin inhibited in vitro staphylococci, 
sarcina, Bacillus subtilis, Diplococcus pneumoniae and Streptococcus pyogenes. 
   
Inhibition occurred at high concentrations, in vitro, compared with commercial 
antibiotics, and thus interest in casecidin languished. Work with casecidin was followed 
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by investigation of a related refined non-immunogenic product of chymosin digestion of 
αs1-casein. 
 
 LONG TERM IMMUNE RESPONSE 
Isracidin was both therapeutic and prophylactic and responses to its therapeutic 
effect produced long-term immune resistance. Isracidin protected mice against Candida 
albicans, by stimulation of both phagocytosis and immune responses. However, like other 
recently described milk-derived peptides, despite its clinical value, isracidin was 
overlooked because of the lack of commercial interest, in the 1970s and early 1980s, in 
host-mediated non-specific resistance as a therapeutic approach to infection. Another 
problem that impeded commercial interest was the isomeric variation in isracidin peptides 
seen on large-scale batch production for commercial use. It is hoped that this review of 
previous studies of the activity of isracidin action will revive interest in milk as an 
antibiotic source. 
 
ANTIVIRAL EFFECTS OF PLASMA AND MILK PROTEINS: LACTOFERRIN 
Native and chemically derivatized proteins purified from serum and milk were 
assayed in vitro to assess their inhibiting capacity on the cytopathic effect of human 
immunodeficiency virus (HIV)-1 and human cytomegalovirus (HCMV) on MT4 cells and 
fibroblasts, respectively.  
Only native and conformationally intact lactoferrin from bovine or human milk, 
colostrum, or serum could completely block HCMV infection (IC50 = 35–100 µg/mL). 
Moreover, native lactoferrin also inhibited the HIV-1-induced cytopathic effect (IC50 = 40 
µg/mL). When negatively charged groups were added to lactoferrin by succinylation, 
there was a 4-fold stronger antiviral effect on HIV-1, but the antiviral potency for HCMV 
infection was mostly decreased. Lactoferrin likely exerts its effect at the level of virus 
adsorption or penetration (or both), because after HCMV penetrated fibroblasts, the 
ongoing infection could not be further inhibited. 
All these components of plays a major role in the management of Neerkana 
mandham by using the trial drug KARAI RASAYANAM. 
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NUTRITIONAL VALUE 
Cow's Milk (whole) Nutritional value per 100 g (3.5 oz) Energy 252 kJ (60 kcal) 
Carbohydrates 5.26 g Sugars 5.26 g Lactose 5.26 g Fat 3.25 g • saturated 1.865 g • 
monounsaturated 0.812 g • polyunsaturated 0.195 g Protein 3.22 g Tryptophan 0.075 g 
Threonine 0.143 g Isoleucine 0.165 g Leucine 0.265 g Lysine 0.140 g Methionine 0.075 g 
Cystine 0.017 g Phenylalanine 0.147 g Tyrosine 0.152 g Valine 0.192 g Arginine 0.075 g 
Histidine 0.075 g Alanine 0.103 g Aspartic acid 0.237 g Glutamic acid 0.648 g Glycine 
0.075 g Proline 0.342 g Serine 0.107 g Water 88.32 g Vitamin A equiv. 28 µg (3%) 
Thiamine (Vit. B1) 0.044 mg (3%) Riboflavin (Vit. B2) 0.183 mg (12%) Vitamin B12 
0.44 µg (18%) Vitamin D 40 IU (10%) Calcium 113 mg (11%) Magnesium 10 mg (3%) 
Potassium 143 mg (3%) 100 mL corresponds to 103 g. Percentages are relative to US 
recommendations for adults. Source: USDA Nutrient databasehttp://puroxi.com/wp-
content/uploads/2011/04/Cows-Milk-Nutritional-Value.pdf 
 
PHYTO NUTRIENTS 
In terms of phytonutrients, you're likely to get 16-40 micrograms of beta-carotene 
in 8 ounces of 100% grass-fed whole cow's milk, along with isoflavones like  
formononetin, 
 biochanin A, 
 and prunetin. 
 You're also like to get lignans like  
Secoisolariciresinol,selenium  
 Matairesinol,zinc.  
Antioxidants include vitamin E  
 
nea; 
 
nghJFzk; : 
“nea;Az Tz;lit Newh;Twr; nra;J Nkd; 
nka;iaAe; jpz;zpa NkUntdr; nra;Ak;” 
 nea;ia Ntz;ba mstha; czTfsps; Nrh;j;Jf; nfhs;s mJ cz;l czit 
rhp gLj;jp rhPuj;jpw;F kpFe;j gyj;ijAk;, G~;biaAk; cz;lhf;Fk; 
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gRtpd; nea; Fzk;   
“jhfKo iyRl;fk; the;jp gpj;jk; thAgpu 
Nkfk; tapw;nwhpT tpf;fy; - khfhrq; 
Fd;kk; twl;rp Flw;Gul;l y];jpRl;fq; 
nrhd;%yk; Nghf;F epiwj; Jg;G” 
 
gRtpd; nea;ahdJ jhfk;,coiyg;gpzp, mjpRl;f Nuhfk;, the;jp, 
gpj;jhjpf;fk;, thjtp~k;, tpuzg; gpuNkfk;, tapw;wpnyhpT, gpj;jtpf;fy;, 
,Uky;, tapW typ Mfpatw;iw jPh;f;Fk;.  
 
GHEE 
Ghee is widely considered as the Indian name for clarified butterfat, usually 
prepared from cow‟s milk.  
 
GHEE IN TRADITIONAL MEDICINE ASPECT *(BOOSTS IMMUNITY ) 
The milk of cows is considered to possess the essence or sap of all plants and 
Ghee is the essence of milk... When we consider Ghee we are in the company of 
superlatives. In India, Ghee has been so highly regarded for so many things, for so long, 
that one is slightly embarrassed to enter into this crowded river of praise. This is what I 
have heard: 
The ingestion of Ghee is like offering the finest of fuels into the fires of digestion-
Agni. In accord with this, Ghee builds the aura, makes all the organs soft, builds up the 
internal juices of the body-Rasa, which are destroyed by aging and increases the most 
refined element of digestion-Shukra or Ojas, the underlying basis of all immunity and the 
“essence of all bodily tissues”. Maya Tiwari calls Ghee the “single most ojas producing 
food on earth”. Ghee is known to increase intelligence--Dhi, refine the intellect-Buddhi 
and improve the memory-Smrti. 
 
NUTRITIONAL VALUE 
Ghee made from grass-fed butter is packed with vitamins A, D, E and K, as well 
as fatty acids CLA and butyric acid . 
Ghee may be composed primarily of fats, but it also contains significant levels 
of vitamin A, vitamin E, andvitamin D. Although many people think of fats as unhealthy 
elements of your diet, the body also needs fat to function. Omega-3s (monounsaturated 
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fats) are healthy forms of fat that can be found in ghee, in addition to other  fatty acids 
like conjugated linoleic acid and butyric acid, both of which have positive health benefits 
in the body.  
 
 CONJUCATED LINOLEIC ACID ( IMMUNI MODULATOR) 
Researchers have deciphered the mechanism of ghee's protective properties. 
'Feeding cow ghee decreased the expression of genes responsible for cell proliferation 
and raised regulated genes responsible for cell apoptosis', explained Dr Vinod Kansal, 
who led the research team.One probable factor in cow ghee is the presence of conjugated 
linoleic acid (CLA), which is known to possess beneficial properties.Cow ghee is a rich 
natural source of CLA, whereas, vegetable oils lack this particular fatty acid. Most 
vegetable oils contain high amount of unsaturated fatty acid as well as linoleic acid - 
which is considered pro-carcinogenic as it forms free radicals known to damage DNA. 
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CANE SUGAR 
DESCRIPTION OF CANE SUGAR 
Cane sugar is the name given to sucrose, a disaccharide produced from the 
sugarcane plant and from the sugar beet. The refined sugars from the two sources are 
practically indistinguishable and command the same price in competitive markets. 
 
SUGARCANE CHARACTERISTICS 
Sugarcane contains not only sucrose but also numerous other dissolved 
substances, as well as cellulose or woody fibre. The percentage of sugar in the cane varies 
from 8 to 16% and depends to a great extent on the variety of the cane, its maturity, 
condition of the soil, climate and agricultural practices followed. 
 
The constituents of ripe cane vary widely in different countries and regions but 
fall generally within the following limits: 
 
Constituent Percentage range Water 69.0 – 75.0 
Sucrose 8.0 – 16.0 
Reducing sugars 0.5 – 2.0 
Organic matter other than sugar 0.5 – 1.0 
Inorganic compounds 0.2 – 0.6 
Nitrogenous bodies 0.5 – 1.0 
Ash 0.3 – 0.8 
Fibre 10.0 – 16.0 
 
ORGANIC COMPOUNDS 
Organic matters other than sugar include proteins, organic acids, pentosan, 
colouring matter and wax. Organic acids present in cane are glycolic acid, malic acid, 
succinic acid and small quantity of tannic acid, butyric acid and aconitic acid. 
 
These vary from 0.5 to 1.0% of the cane by weight. The organic compounds are 
made up of phosphates, chlorides, sulphates, nitrates and silicates of sodium, potassium, 
calcium, magnesium and iron chiefly. These are present from 0.2 to 0.6%.The 
nitrogenous bodies are albuminoid, amides, amino acids, ammonia, xanthine bases, etc. 
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These are present to theextent of 0.5 to 1.0%. Fibre is the insoluble substance in the cane. 
Dry fibre contains about 18.0% lignin, 15% water-soluble substances, 45% cellulose and 
the rest hemicellulose. 
 
 
 
PHARMACOLOGICAL ACTIVITY 
Sugarcane contains various phytochemicals including phenolic compounds, plant 
sterols, and policosanols. Phenols help in the natural defense of plants against pests and 
diseases, while plant sterols and policosanols are the components of wax and plant oils.  
 
The phytochemicals have gained increased interest due to their antioxidant 
activity, cholesterol-lowering properties, and other potential health benefits. Several 
workers have reported the different biological activities of sugarcane in various in-
vivo and in-vitro test models. 
 
ANALGESIC ACTIVITY 
Ethanol extracts (95%) of both fresh leaves and shoots were administered 
intragastrically to mice at a dose of 1 g/kg. The leaf extracts were active against benzoyl 
peroxide-induced writhing and tail-flick response, but ethanol extract of shoots were 
active only against the tail-flick method. 
 
ANTI-INFLAMMATORY EFFECT 
Mixtures of fatty acids isolated from sugarcane wax were examined for their anti-
inflammatory effect on both rats and mice. Oral administration of this mixture showed 
anti-inflammatory activity in the cotton pellet granuloma assay .  
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4.MATERIALS AND METHODS 
  
PREPARATION OF KARAI RASAYANAM 
 
The ingredients for preparation of experimental formulation  KARAI 
RASAYANAM is  purchased from a well reputed country shop and raw drugs were 
authenticated byAssistant  Professor of  MEDICINAL BOTANY DEPARTMENT 
NATIONAL INSTITUTE OF SIDDHA. 
  
The medicine was prepared in Gunapadam laboratory of National Institute of 
Siddha after proper purification.The prepared medicine was also authenticated by the 
GUNAPADAM BRANCH , Head of the Department  for its completeness. 
 
INGREDIENTS: 
KARAI PAZHAM – Canthium parviflorum(fig : 2) 
COW MILK – Pasum paal(fig : 3) 
CANE SUGAR – Karumbu sarkarai(fig : 4) 
GHEE – Pasu nei(fig : 5) 
 
METHOD OF PURIFICATION: Karai pazham is washed thoroughly with a 
plain drinking water. 
 
QUANTITY OF THE DRUGS:  
Karai fruit juice(Canthium parviflorum)      - 1.3 litres 
                                    Cow milk                -5.2 litres 
                                    Ghee                       -325 ml 
                                    Sugar                      -1.3 litres 
 
METHOD OF PREPARATION : 
In a mud pot add karai juice,cow milk,sugar and heat it till it attains a thick 
semisolid form, at that time add ghee and complete the preparation. 
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Dose   : 4 ml bid 
Duration  : 7 days 
Drug Storage : Prepared medicine is stored in clean and dry glass container. 
Dispensing :  Prepared medicine is given in a  separate air tight container in individual 
dosages. 
Indication  :All types of kanam. 
Reference  : Balavagadam 4
th
 edition Indian Medicine and Homeopathy Dept 
Thiruvalar nevinar printers chennai, K.S. murugaesa mudhaliyar. 
 
 
 
INGREDIENTS OF KARAI RASAYANAM 
 
  
Figure2:KARAIPAZHAM 
(Canthiumparviflorum ) 
 
 
 
 
Figure 3 : COW MILK (Pasumpaal ) 
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Figure 4 : CANE SUGAR       
 (Karumbu sarkarai ) 
 
Figure 5 : GHEE (Pasu nei ) 
 
 
Fig 6: KARAI RASAYANAM (Trial drug ) 
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PRECLINICAL STUDIES  
Physicochemical Analysis  
Chemical Analysis  
Pharmacological Activity 
 
PHYSICOCHEMICAL ANALYSIS OF KARAI RASAYANAM 
The Physicochemical analysis of the drug MN was done at Captain Srinivasmoorthy Drug 
Research Institute (CSMDRI), Arumbakkam Chennai. Since the form of the drug is in 
Rasayanam. 
 
The parameters such as 
 
RANCIDITY  
ACID VALUE 
SAPONIFICATION VALUE 
PEROXIDASE VALUE 
IODINE VALUE 
FAT CONTENT 
 
Rancidity test (Kreis Test)  
 
The test depends upon the formation of a red colour when oxidized fat is treated 
with conc. HCl and a solution of phloroglucinol in ether. The compound in rancid fats 
responsible for the colour reaction is epihydrin aldehyde. All oxidized fats respond to the 
Kreis test and the intensity of the colour produced is roughly proportional to the degree of 
oxidative rancidity. Procedure Mix 1 ml of melted fat and 1 ml of conc. HCl in a test 
tube. Add 1 ml of a 1 % solution of phloroglucinol in diethyl ether and mix thoroughly 
with the fat-acid mixture. A pink colour formation indicates that the fat is slightly 
oxidized while a red colour indicates that the fat is definitely oxidized.  
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Acid value 
The acid value is a measure of the amount of free acids present in a given amount 
of fat.The lipids are extracted from the food sample and then dissolved in an ethanol 
solution containing an indicator. This solution is then titrated with alkali (KOH) until a 
pinkish color appears. The acid value is defined as the mg of KOH necessary to neutralize 
the fatty acids present in 1g of lipid. The acid value may be overestimated if other acid 
components are present in the system, e.g. amino acids or acid phosphates. The acid 
value is often a good measure of the break down of the triacylglycrols into free fatty 
acids, which has an adverse effect on the quality of many lipids. 
 
Saponification value 
It is a measure of the average molecular weight (or chain length) of all the fatty 
acids present. As most of the mass of a fat/tri-ester is in the 3 fatty acids, it allows for 
comparison of the average fatty acid chain length. The long chain fatty acids found in fats 
have a low saponification value because they have a relatively fewer number of 
carboxylic functional groups per unit mass of the fat ascompared to short chain fatty 
acids. If more moles of base are required to saponify Ngrams of fat then there are more 
moles of the fat and the chain lengths are relatively small,given the following relation: 
Number of moles = mass of oil/relative atomic mass The calculated molar mass is not 
applicable to fats and oils containing high amounts of Un saponifiable material, free fatty 
acids (>0.1%), or mono- and diacylglycerols (>0.1%). 
 
Peroxide value 
The peroxide value is determined by measuring the amount of iodine which is 
formed by the reaction of peroxides (formed in fat or oil) with iodide ion. 
2 I− + H2O + HOOH -> HOH + 2OH− + I2 
 
Fat content 
These methods are based on mixing the sample and the solvent in a suitable 
container,e.g., a separatory funnel. The container is shaken vigorously and the organic 
solvent andaqueous phase are allowed to separate (either by gravity or centrifugation). 
The aqueousphase is then decanted off, and the concentration of lipid in the solvent is 
determined by   evaporating the solvent and measuring the mass of lipid remaining: 
%Lipid = 100 � 
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(Mlipid/Msample). This procedure may have to be repeated a number of times to improve 
the efficiency of the extraction process. In this case the aqueous phase would undergo 
further extractions using fresh solvent, then all the solvent fractions would be collected 
together and the lipid determined by weighing after evaporation of solvent. The efficiency 
of the extraction of a particular type of lipid by a particular type of solvent can be 
quantified by an equilibrium partition coefficient, K = csolvent/caqueous, where csolvent 
and caqueous are the concentration of lipid in the solvent and aqueous phase, 
respectively.  The higher the partition coefficient the more efficient the extraction 
process. 
 
Iodine value 
This particular analysis is an example of iodometry. A solution of iodine is 
yellow/brown in colour. When this is added to a solution to be tested, however, any 
chemical group (usually in this test C=C double bonds) that react with iodine effectively 
reduce the strength, ormagnitude of the colour (by taking iodine out of solution). Thus the 
amount of iodinerequired to make a solution retain the characteristic yellow/brown colour 
can effectively beused to determine the amount of iodine sensitive groups present in the 
solution. 
 
PHARMACOLOGICAL ACTIVITY 
Anti-Inflammatory Activity Of Karai Rasayanam 
Inhibition Of Albumin Denaturation 
 
The reaction mixture (5 ml) consisted of 0.2 ml of egg albumin (from fresh hen‟s 
egg), 2.8 ml of phosphate buffered saline (PBS, pH 6.4) and 2 ml of varying 
concentrations of the test extract. Similar volume of double-distilled water served as 
control. Then the mixtures were incubated at 37±2ºC in an incubator for 15 minutes and 
then heated at 50ºC for 5 minutes. After cooling, their absorbance wasmeasured at 660 
nm (SHIMADZU, UV 1800) by using vehicle as blank. Diclofenacsodium was used as 
reference drug and treated similarly for determination of absorbance (Dey et al., 2011; 
Chandra et al., 2012).  
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The percentage inhibition of protein denaturation was calculated by using 
thefollowing formula: 
% Inhibition of Protein Denaturation = 100 x [Vc – Vt / Vc] 
 
Where, Vt = absorbance of test sample, Vc = absorbance of control. The extract/drug 
concentration for 50% inhibition (IC50) was determined form the doseresponse curve by 
plotting percentage inhibition with respect to control against treatment concentration. 
 
Reference: Dey P., Chatterjee P., Chandra S., Bhattacharya S. Comparative in vitro 
evaluationof anti-inflammatory effects of aerial parts and roots from Mikania scandens. J. 
Adv.Pharm. Edu. Res. 2011; 1 (6): 271-277.Chandra S., Chatterjee P., Dey P., 
Bhattacharya S. Evaluation of anti-inflammatoryeffect of ashwagandha: a preliminary 
study in vitro. Phcog. J. 2012; 4 (29): 47-49 
 
Membrane ( Human Red Blood Cells) stabilization test 
 
Drug used as Standard: Acetylsalicylic acid available in the commercial name of 
Ecosprin ʀ -75 marketed by USV Limited, Mumbai, Maharashtra was used as a source of 
Acetylsalicylic acid.  
 
Human Blood: The blood was collected from a healthy human volunteer who had not 
taken any NSAIDS for 2 weeks prior to the experiment and collected in heparinized 
vacutainer. The blood was washed three times with 0.9% saline and centrifuged 
simultaneously for 10 minutes at 3000 rpm. The packed cells were washed with 0.9% 
saline and a 40% v/v suspension made using isotonic phosphate buffer which was 
composed of 154mM NaCl in 10mM Sodium Phosphate Buffer at pH 7.4 used as Stock 
erythrocyte or RBC suspension.  
 
Hypotonic solution –induced haemolysis or membrane stabilizing activity: This test 
was done according to the method described (Shinde et al., 1999) with slight 
modifications. The test sample consisted of stock erythrocyte (RBC) suspension 0.030ml 
mixed with 5ml of hypotonic solution (154mM NaCl in 10mM Sodium Phosphate Buffer 
at pH 7.4) containing testextract ranging from concentration 1.56 -50 mg/ml. The control 
sample consisted of 0.030ml RBC suspension mixed with hypotonic buffered solution 
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alone. The standard drug acetylsalicylic was treated similar to test at 78.125, 156.25, 
312.5, 625, 1250 µg/ml concentrations. The experiment was carried out in triplicate. The 
mixtures were incubated at 10 minutes at room temperature, centrifuged for 10 minutes at 
3000rpm and absorbance of the supernatant was measured spectrophotometrically at 540 
nm.  
 
The percentage inhibition of haemolysis or membrane stabilization was calculated by 
following equation.  
% Inhibition of haemolysis = 100 x [A 1 –A 2 /A 1] 
 
Where:  
A 1 = Absorbance of hypotonic buffered solution alone  
A 2 = Absorbance of test /standard sample in hypotonic solution 
 
Reference: 
Shinde U A, Phadke AS, Nair AM, Mugantiwar AA, Dikshit VJ and Saraf VO 
(1999).Membrane stabilizing activity –a possible mechanism of action for the anti-
inflammatory activity of Cedrus deodara wood oil. Fitoterapia 70 (3) 251-257. 
 
CHEMICAL ANALYSIS OF  KARAI RASAYANAM 
The chemical analysis of KARAI RASAYANAM was carried out in Bio 
chemistry Lab, National Institute Of Siddha Chennai. 
 
PREPARATION OF EXTRACT: 
   5ml of sample was taken in a 250ml clean beaker and added with 50ml of distilled 
water. Then it is boiled well for about 10 minutes. Then it is cooled and filtered in a 
100ml volumetric flask and made up to 100ml with distilled water.  
This preparation is used for the qualitative analysis of acidic/basic radicals and chemical 
constituents in it. 
 
Procedure: 
Test for Silicate 
A 2ml of the sample was shaken well with distilled water. 
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Action of Heat: 
A 2ml of the sample was taken in a dry test tube and heated gently at first and then 
strong. 
 
Action of Heat: 
A 2ml of the sample was taken in a dry test tube and heated gently at first and then 
strong. 
 
Ash Test: 
A filter paper was soaked into a mixture of extract and dil. cobalt nitrate solution 
and introduced into the Bunsen flame and ignited 
 
I. Test for Acid Radicals 
Test for Sulphate: 
2ml of the above prepared extract was taken in a test tube to this added 2ml of 4% 
dil ammonium oxalate solution 
 
Test for chloride: 
2ml of the above prepared extracts was added with 2ml of dil.HCl is added until 
the effervescence ceases off. 
 
Test for Phosphate: 
2ml of the extract were treated with 2ml of dil.ammonium molybdate solution and 
2ml of con.HNo3. 
 
Test for carbonate: 
2ml of the extract was treated with 2ml of dil. magnesium sulphate solution. 
 
Test for Nitrate: 
1gm of the extract was heated with copper turning and concentrated H2So4 and 
viewed the test tube vertically down. 
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II.Test for Basic radicals 
Test for lead: 
2ml of the extract was added with 2ml of dil.potassium iodine solution. 
Test for copper: 
One pinch (25mg) of extract was made into paste with con. HClin a watch glass 
and introduced into the non-luminuous part of the flame. 
Test for Aluminium: 
To the 2ml of extract dil.sodium hydroxide was added in 5 drops to excess. 
Test for Iron: 
a. To the 2ml of extract add 2ml of dil.ammonium solution 
b. To the 2ml of extract 2ml of thiocyanate solution and 2ml of con HNo3 is 
added. 
Test for Zinc:Test for Calcium: 
To 2ml of the extract was added with 2ml of 4% dil.ammonium oxalate solution 
Test for Magnesium: 
To 2ml of extract dil.sodium hydroxide solution was added in drops to excess. 
Test for Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent and excess of dil.sodium hydroxide 
solution are added. 
Test for Potassium: 
A pinch (25mg) of extract was treated of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt nitrate in 30% dil.glacial acetic acid. 
 
Test for Sodium: 
2 pinches (50mg) of the extract is made into paste by using HCl  and introduced 
into the blue flame of Bunsen burner. 
To 2ml of the extract dil.sodium hydroxide solution was added in 5 drops to 
excess and dil.ammonium chloride is added. 
Test for Mercury: 
2ml of the extract was treated with 2ml of dil.sodium hydroxide solution. 
Test for Arsenic: 
2ml of the extract was treated with 2ml of dil.sodium hydroxide solution 
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III. Miscellaneous 
Test for Starch: 
2ml of extract was treated with weak dil.Iodine solution. 
Test For Reducing Sugar: 
5ml of Benedict's qualitative solution was taken in a test tube and allowed to boil 
for 2 minutes and added 8 to 10 drops of the extract and again boil it for 2 minutes. The 
colour changes are noted. 
Test for the Alkaloids: 
a) 2ml of the extract was treated with 2ml of dil.potassium Iodide solution. 
b) 2ml of the extract was treated with 2ml of dil.picric acid. 
c) 2ml of the extract was treated with 2ml of dil.phosphotungstic acid. 
Test for Tannic Acid: 
2ml of extract was treated with 2ml of dil.ferric chloride solution. 
Test for Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium permanganate solution is added. 
 
Test for AminoAcid: 
2 drops of the extract was placed on a filter paper and dried well. 20ml of Burette 
reagent is added. 
Test for Type of Compound: 
2ml of the extract was treated with 2 ml of dil.ferric chloride solution. 
 
CLINICALSTUDIES  
All the 40 cases were selectedfromthe OPD and IPD of Kuzhandhai  Maruthuvam 
Department, NationalInstituteof Siddha. They weretreated withthetrialdrug  Karai 
rasayanam and observed for prognosisclinically.  
 
STUDY DESIGN & CONDUCT OF STUDY. 
Studytype :An open clinical study  
Studyplace: OPD, IPD  Of Ayothidass  pandithar  hospital, 
 National Institute of Siddha, 
Tambaram, sanatorium, Chennai-47.  
Studyduration: 12Months  
Treatment period :7 days  
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Population and sample: Populationconsistsof   pediatric   patientsattending   the 
OPD, Department of Kuzhandhai Maruthuvam  of Ayothidoss   Pandithar Hospital,  
National Institute of  Siddha, Chennai-47. 
Thesampleconsistsofpatients3- 7yearsagegroupfulfilling the major  
 inclusion  criteriaand exclusioncriteria.  
 
INCLUSION CRITERIA    
Patientwhocomplainedwithsymptoms of  Neerkanamandham like , 
Symptoms of cough 
               Running nose 
               Fever 
               History of diarrhea/Flatulence  
Age: 3-7yearsofbothsex. 
Parent/guardian of the Patient willing to sign the informed consent. 
Patients who are willing to accept radiological investigation and provide blood sample for 
lab investigation when required. 
 
EXCLUSION CRITERIA 
Children below 3 years and above 7 years age 
H/O  Primary complex , pneumonia , bronchial asthma 
Continous fever for more than five days 
Signs of dehydration 
Breathing difficulties 
Patients with any other serious illness. 
Sample size : 40patients  
TREATMENTMEDICINENAME : KARAI RASAYANAM 
DOSAGE     :  3-7yrs        4ml  ( bd )   
DURATION     :  7days  
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STUDYENROLLMENT  
Patients  reporting  at theOPD  with the clinical symptoms of Cough,   
Rhinorrhoea, Intermittent fever,  Headache,   Malaise, Diarrhoea will be examined 
clinically for enrolling in this study based  on the       inclusion and exclusion criteria.  
The patients who were en rolled and the irparents were informed about the study, trial 
drug, possible out comes and the objectives of the study in the language and           terms 
understandable to them.  
After as certaining   the   patients willingness, informed   consent(FormII) was  obtained 
in writing from their parents in the consent form.  
Complete clinical history,complaints and duration, examination findings were  recorded 
in the prescribed Proforma in the history and clinical assessment forms separately.  
Screening Form- I was filled up. Form III,   Form–IV and Form–V were used for   
recording the patient‟s history, clinical examination of   symptoms and signs and 
laboratory investigations respectively.  
Patient were advised to take the trial drug and  appropriate dietary advice was given 
according to the patient‟s perfect understanding . 
 
CONDUCT OF THE STUDY  
Neerkana Mandham  patients  satisfying  inclusion & exclusion criteria are admitted to 
the trial. Informed consent will be obtained from patients. Investigations are carried out before 
treatment  and at the end of the treatment.  
The  trial  drug  KARAI RASAYANAM is given continuously for 7 days. Patients 
are asked to come on 8
th
 day in clinical visit and clinical assessment is done and 
prognosis . After the end of the treatment  patient were advised to visit the OPD for 2 
months.  
 
DATAMANAGEMENT 
After enrolling the patient in the study, a separate file for each patient was opened 
and all forms were filed in the file. The Data recordings were monitored for completion 
and adverse event.  
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The followingASSESSMENT FORMSwereusedfor datacollection:  
FORM I  SCREENING & SELECTION PROFORMA ( Ref : ANNEXURE I) 
FORM II PATIENT‟S  INFORMATION SHEET ( Ref : ANNEXURE II) 
FORM III CONSENT  FORM  ( Ref : ANNEXURE III) 
FORM IV  CASE  REPORT  FORM ( Ref : ANNEXURE IV) 
FORM V DRUG  COMPLIANCE ( Ref : ANNEXURE V) 
FORM VI        WITHDRAWL  FORM  ( Ref : ANNEXURE VI) 
FORMVII        ADVERSE  REACTION FORM ( Ref : ANNEXUREVII) 
FORM VIII     NATIONAL  PHARMACO VIGILANCE  ( Ref : ANNEXURE VIII) 
FORM IX        DIETARY ADVICE ( Ref : ANNEXURE IX) 
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5.RESULTS AND OBSERVATIONS 
 
PRE  CLINCIAL STUDIES  
Table 1 :Physicochemical analysis of the karai rasayanam 
S.No. Parameters Results 
1                Rancidity Nil 
2                Acid value  1.4596 
3 Saponification value 159.8711 
4                 Peroxide value Nil 
5                 Iodine value 19.2043 
6                 Fat content 14.7037 
 
CHEMICAL ANALYSIS OF KARAI RASAYANAM  
chemical Analysis of KARAI RASAYANAM was done at the Biochemistry lab at 
National Institute of Siddha, Chennai by the method of Kolkate (1). 
 
Preparation of Extract:  5ml of is weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 
minutes. Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml 
with distilled water. 
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Table 2 : Chemical analysis of Karai Rasayanam 
S.
No 
EXPERIMENT OBSERVATION INFERENCE 
1.  Physical Appearance of sample Yellow  in colour  
2. Solubility: 
a. A little (500mg) of the sample is shaken well 
with distilled water. 
b. A little (500mg) of the sample is shaken well 
with con. HCl/ Con. H2So4. 
   Not  soluble 
 
 
Presence of 
silicate 
3. Action of Heat: 
   A small amount (500mg) of the sample is 
taken in a dry test tube and heated gently at 
first and then strong. 
White fumes 
evolved 
 
 
Presence 
of Copper 
 
4. Flame Test: 
  A small amount (500mg) of the sample is 
made into a paste with con. HCl in a watch 
glass and introduced into non-luminous part of 
the Bunsen flame. 
No Bluish green 
flameappeared. 
Absence of 
Copper 
5. Ash Test: 
A filter paper is soaked into a mixture of 
sample and dil. cobalt nitrate solution and 
introduced into the Bunsen flame and ignited 
No Yellow 
coloured flame 
Absence  of 
Sodium 
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S.No 
EXPERIMENT 
 
OBSERVATION INFERENCE 
I. TEST FOR ACID RADICALS 
1. Test For Sulphate: 
a.2ml of the above prepared extract is taken in 
a test tube to this added 2ml of 4% dil. 
ammonium oxalate solution 
Cloudy 
appearance 
present 
Presence  
of  Sulphate 
2. Test For Chloride: 
2ml of the above prepared extracts is added 
with 2ml of dil-HCl is added until the 
effervescence ceases off. 
Cloudy  
appearance 
present 
Presence  
of Chloride 
3. Test For Phosphate: 
2ml of the extract is treated with 2ml of 
dil.ammonium molybdate solution and 2ml of 
con.HNo3 
No cloudy yellow 
appearance 
present 
Absence 
of  Phosphate 
4  Test For Carbonate: 
2ml of the extract is treated with 2ml dil. 
magnesium sulphate solution. 
Cloudy 
appearance 
present 
Absence  
of  Carbonate 
5 Test For Nitrate: 
1gm of the substance is heated with copper 
turning and concentrated H2So4 and viewed 
the test tube vertically down. 
No Brown gas  
evolved 
Absence  
of Nitrate 
6. Test For Sulphide: 
1gm of the substance is treated with 2ml of 
con. HCL 
Rotten Egg 
Smelling gas 
evolved 
Absence  
of  Sulphide 
7. Test For Fluoride & Oxalate: 
2ml of extract is added with 2ml of dil. Acetic 
acid and 2ml dil.calcium chloride solution and 
heated. 
No Cloudy         
appearance 
Absence  
of Fluoride 
and Oxalate 
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8. 
 
Test For Nitrite: 
3drops of the extract is placed on a filter 
paper, on that-2 drops of dil.acetic acid and 2 
drops of dil. Benzidine solution is placed. 
No characteristic 
Changes 
Absence  
of  Nitrite 
9. Test For Borate: 
2 Pinches (50mg) of the substance is made 
into paste by using dil.sulphuric acid and 
alcohol (95%) and introduced into the blue 
flame. 
Bluish green 
colour flame did 
not appear. 
   Absence  
of  Borate 
II. TEST FOR BASIC RADICALS 
1. Test For Lead: 
2ml of the extract is added with 2ml of 
dil.potassium iodine solution. 
No Yellow 
Precipitate is 
obtained. 
Absence of 
Lead 
2. Test For Copper: 
a. One pinch(50mg) of substance is made into 
paste with con. HClin a watch glass and 
introduced into the non-luminuous part of the 
flame. 
 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
Absence 
of Copper 
3. Test For Aluminium: 
To the 2ml of extract dil.sodium hydroxide is 
added in 5 drops to excess. 
characteristic 
changes 
  Presence  
of Aluminium 
4. Test For Iron: 
a.To the 2ml of extract add 2ml of 
dil.ammonium solution 
b.To the 2ml of extract 2ml  thiocyanate 
solution and 2ml  of con HNo3 is added 
 
Red colour 
appeared 
Absence of 
iron 
 
5. Test For Zinc: 
    To 2m1 of the extract sodium 
hydroxide solution is added in 
drops to excess. 
White precipitate  
Formed 
 
Absence of 
zinc 
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6. Test For Calcium:  
2ml of the extract is added with 2ml of 4% 
dil.ammonium oxalate solution  
Cloudy 
appearance and 
white precipitate  
was not obtained. 
   Presence 
of  Calcium 
7. Test For Magnesium:  
To 2ml of extract dil.sodium hydroxide 
solution is added in drops toexcess. 
White precipitate 
was  obtained 
   Presence of  
Magnesium 
8. Test For Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent and 
excess of dil.sodium hydroxide solution are 
added. 
Brown colour 
appeared 
     presence  
of Ammonium 
9. Test For Potassium: 
   A pinch (25mg) of substance is treated of 
with 2ml of dil.sodium nitrite solution and 
then treated with 2ml of dil.cobalt nitrate in 
30% dil.glacial acetic acid. 
 
No Yellowish 
precipitate was 
obtained. 
 
   Absence  
of  Potassium 
10. Test For Sodium: 
    2 pinches (50mg) of the substance is made 
into paste by using HCl and introduced into 
the blue flame of Bunsen burner. 
 No Yellow 
coloured flame 
appeared 
Absence 
of  Sodium 
11. Test For Mercury:  
   2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained. 
Absence of 
Mercury 
12. Test For Arsenic:  
   2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution. 
No brownish red 
precipitate was 
obtained. 
Absence 
of Arsenic 
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III. MISCELLANEOUS 
1.
  
Test For Starch: 
2ml of extract is treated with weak 
dil.Iodine solution  
 
No Blue colour 
developed 
 
Absence  
of  Starch 
2.
  
Test For Reducing Sugar: 
    5ml of Benedict's qualitative solution is 
taken in a test tube and allowed to boil for 
2 minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes. The 
colour changes are noted. 
 
 
    Red colour not 
developed 
 
Presence  of 
Reducing 
sugar. 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract is treated with 2ml of 
dil.potassium lodide solution. 
b)  2ml of the extract is treated with 2ml of 
dil.picric acid. 
c)  2ml of the extract is treated with 2ml of 
dil.phosphotungstic acid. 
 
Red colour  not 
developed 
 
Yellow colour not 
developed 
White precipitate  not 
developed 
 
Presence of 
Alkaloid 
4.
  
Test For Tannic Acid:  
2ml of extract is treated with 2ml of 
dil.ferric chloride solution  
 
No black precipitate 
was obtained 
Absence of 
Tannic acid 
5.
  
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium 
permanganate solution is added.  
 
Potassium 
permanganate is not 
decolourised 
 
Absence of 
unsaturated 
compound 
6.
  
Test For Amino Acid: 
2 drops of the extract is placed on a filter 
paper and dried well. 20ml of  Biurette 
reagent is added. 
 
No Violet colour 
developed 
 
   Absence   
of Amino 
acids 
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7. Test For Types of Compound: 
2ml of the extract is treated with 2 ml of 
dil.ferric chloride solution.  
 
No Green colour 
developed 
 
 
 
No Red colour 
developed 
 
 
 
No Violet colour 
developed 
 
 
 
No blue colour 
Developed 
Absence of 
oxy 
quinole 
epinephrine 
and pyro 
catechol. 
Anti pyrine, 
Aliphatic          
amino acids 
and Meconic 
acid are 
absent. 
Apomorphine, 
Salicylate and 
Resorcinol are 
absent. 
Morphine, 
Phenol 
cresol and 
hydro 
quinone are 
absent 
 
 
Results of Acid radicals studies 
S.NO Parameter Observation Result 
1 Test for Sulphate  
- 
Negative 
2 Test for Chloride 
 
Cloudy appearance 
present 
 
Positive 
3 Test For Phosphate 
 
 
- 
 
Negative 
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4 Test For Carbonate   
 
 
 
- 
 
          Negative                                                      
 
5 Test For Nitrate  
- 
Negative 
6 Test for Sulphide  
- 
Negative 
7 Test For Fluoride &oxalate 
 
 
- 
Negative 
8 Test For Nitrite 
 
- 
 
Negative 
9 Test For Borax 
 
- Negative 
 
Interpretation 
The acidic radicals test shows the presence ofChloride 
Results of basic radicals studies. 
S.NO Parameter Observation Result 
1 Test for Lead  
- 
Negative 
2 Test for Copper 
 
- Negative 
3 Test For Aluminium 
. 
 
- 
Negative 
4 Test For Iron 
. 
- Negative 
5 Test For Zinc  
- 
Negative 
6 Test for Calcium  
- 
Negative 
7 Test For Magnesium 
 
 
- 
 
Negative 
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8 Test For Ammonium 
 
Mild brown colour 
appears.  
 
Positive 
 
9 Test For Potassium 
 
- Negative 
10  Test For Sodium 
 
 
- 
 
Negative 
11 Test For Mercury 
 
 
- 
 
Negative 
12 Test For Arsenic 
 
 
- 
 
- Negative 
 
Interpretation 
 The basic radical test shows the presence of, Ammonium, and absence of heavy 
metals such as lead, arsenic and mercury. 
 
PHARMACOLOGICAL ACTIVITY 
Assessment Of Invitro Anti-Inflammatory Activity 
INHIBITION OF ALBUMIN DENATURATION 
Table: 3. Influence of Karai rasayanam against Protein Denaturation  
 
S.No Concentration (mg / mL) % Inhibition of Protein Denaturation 
1 10 36.75 
2 20 58.32 
3 30 72.44 
4 40 85.61 
5 50 93.87 
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Influence of Karai rasayanam against Protein Denaturation 
 
 
 
 
 
 
 
 
 
 
 
Table: 4. Influence of Diclofenac Sodium against Protein Denaturation 
 
S.No Concentration ( mg / mL) % Inhibition of Protein Denaturation 
1 0.078 39.4 
2 0.156 57.1 
3 0.312 64.8 
4 0.625 72.5 
5 1.250 95.2 
 
Influence of Diclofenac Sodium against Protein Denaturation 
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Table: 5. IC50 values of Karai rasayanamand Diclofenac Sodium against  
Protein Denaturation 
 
S.No Treatments IC50 values ( mg / mL) 
1 Karai rasayanam 16.294 
2 Diclofenac Sodium 0.098 
 
Membrane ( Human Red Blood Cells) stabilization test 
Table: 6. Influence of Karai rasayanam against Membrane Stabilization 
 
S.No Concentration (mg / mL) % Inhibitionof Haemolysis 
1 0.78 12.8 
2 1.56 26.5 
3 3.125 40.7 
4 6.25 62.5 
5 12.5 81.9 
 
 
Influence of Karai rasayanam against Membrane Stabilization 
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Table:7 IC50 values of Karai rasayanam and Acetylsalicylic acid against  
Membrane Stabilization 
 
S.No Treatments IC50 values ( mg / mL) 
1 Acetylsalicylic acid 0.1918 
2 Karai rasayanam 5.762 
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CLINICAL STUDIES  
For this clinical study 40 cases were selected and treated in the Out patient  
department and In-patient department of  Kuzhanthai Maruthuvam, Ayothidoss Pandithar 
Hospital NIS, Chennai 47. Results were observed with respect to the following criteria.  
 
Results were observed with respect to the following criteria:  
1. Age Distribution  
2. Sex Distribution  
3. Socio-Economic Status  
4. Immunization History 
5. Diet Reference 
6. Reference To Thinai 
7. Seasonal Reference  
8. Reference To Mukkutrangal 
     8 (A) Vadham 
     8 (B) Pitham 
     8 (C) Kabam 
9. Reference To Udal Kattugal 
10.Reference To Enn Vagai Reference Thervu 
11. Neikuri Reference  
12.Reference To Clinical Features – 
     12 (A) Modified Leister‟s Assessment Scale For Cough (Ref:                              
Annexure - X) 
     12 (B) Rhinitis Quesstionnaire 
     12 (C) Other Clinical Symptoms 
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Table 8: Distributions of patients with Neerkanamantham according to 
Age 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:Pie chart reference to age. 
 
Inference: 
 Out of 40 patients, 75% of cases were 3-4 years, 25% were 5-7 years. So the age 
between 3 – 4 preschool age children were affected the most. 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Age No of cases Percentage 
1. 3-4 Years 30 75 
2. 5-7Years 10 25 
75%
25%
AGE
3-4 Years
5-7Years
Age
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Table 9: Distributions of patients with Neerkanamantham   according to 
Gender 
 
 
 
 
Figure 8:Pie diagram reference to gender 
 
Inference: 
Out of 40 patients 50% were male children and 50% were female children .So 
there is no marked difference in sex distribution and this diseasecan affect either sex. 
  
50%50%
GENDER
Male Child
Female Child
S.no Sex No of Cases Percentage 
1. Male Child 20 50 
2. Female Child 20 50 
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TABLE 10 : Distributions of patients with Neerkanamantham   
according to Gender 
 
S.No 
Socio-economic 
Status 
No of Cases Percentage 
1. Poor 20 50 
2. Middle class 13 32 
3. Rich 7 18 
  
 
Figure 9 :Bar diagram reference to Socio economic status 
 
Inference: 
 About 50% patients were under lower income group, 32% patients were 
under middle income group and 18% patients were under high income group.  The 
highest incidence occurred in lower income group. 
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Table 11 :Distributions of patients with Neerkanamantham   according 
to Immunization history 
S.No Immunization No of Cases Percentage 
1. Complete  27 67 
2. Incomplete  10 25 
3. 
Complete but time 
lag 
3 7.5 
 
 
Figure 10:Bar diagram reference to Immunization 
 
Inference : 
About 27 %children were completely immunized , 10 % children incompletely 
immunized and 3 % were immunized with time lag .Hence immunization doesn‟t play a 
major role. 
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Table 12: Distributions of patients with Neerkanamantham   according 
to Diet 
 
 
 
Figure 11:Bar diagram reference to Food habits 
 
Inference: 
 According to diet, high incidence of cases (80%) was noted in mixed and in 
vegetarian 20% cases were noted. 
  
20
80
0
10
20
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70
80
90
Vegetarian Mixed
Food habits
Vegetarian
Mixed
S.No Food habits No.of Cases Percentage 
1. Vegetarian 8 20 
2. Mixed 32 80 
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Table 13 :Distributions of patients with Neerkanamantham   according 
to Nilam 
Nilam No of cases Percentage 
Kurinji  0 0 
Mullai  1 2.5 
Marutham  6 15 
Neithal  33 82.5 
Paalai  - - 
 
 
Figure 12:Bar diagram reference to Nilam 
 
Inference: 
Among 40 patients, 82.5% were from Neithal land, 15.% from Marutham land, 2.5% 
from Mullai land. 
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Table 14: Distributions of patients with Neerkanamantham   according 
to Paruvakaalam 
 
S.No Paruvakaalam No. of cases Percentage 
1. Karkaalam (Avani – puratasi) 15 37.5 
2. Koothirkaalam (Iyppasi – karthikai) 1 2.5 
3. Munpani (Markazhi – Thai) 1 2.5 
4. Pin pani (Masi – Panguni) 14 35 
5. Elavenil (Chitirai, Vaigasi) 1 2.5 
6. Mudhuvenil (Aani, Aadi) 8 20 
 
 
 
Figure 13:Bar diagram reference to Paruvakaalam 
 
Inference: 
According to paruva kaalam, high incidence of cases 37.5% were reported inKaaa kalam 
and 35.% cases were from Pinpani kaalam. 
0
37.5
2.5 2.5
35
2.5
20
Paruvakalam
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Table 15 a :Distributions of patients with Neerkanamantham  according 
to Mukktrangal – 15 a. Vadham 
 
 
 
Figure 14 a:Bar diagram reference to Vadham derangement 
 
Inference: 
 `According to vatham, derangement of Pranan, Uthanan, samanan was 100%, 
kirukaran was affected 90% andabanan was deranged in45%. 
S.No 
Classification of 
vatham 
No. of Cases Percentage 
1. Pranan 40 100 
2. Abanan 18 45 
3. Viyanan 28 70 
4. Uthanan 40 100 
5. Samanan 40 100 
6. Nagan 0 0 
7. Koorman 0 0 
8. Kirukaran 36 90 
9. Devathathan 0 0 
10. Thananjeyan 0 0 
0
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90
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TABLE15 (b) PITHAM 
 
S.No Types of pitham No.of Cases Percentage 
1. Analapitham 36 90 
2. Ranjagam 18 45 
3. Saathagam 19 47.5 
4. Prasagam 0 0 
5. Alosagam 0 0 
 
 
Figure 14 b.:Bar diagram reference to Pitham derangement 
 
Inference: 
According to Pitham, derangement of Analapitham was 90%, Sathagam was 
deranged in  47.5 %%, Ranjekam was 45 %. 
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Table 15 (c)  :  KABAM. 
S.No Types of Kabham No.of Cases Percentage 
1. Avalambagam 40 100 
2. Kilethagam 36 90 
3. Pothagam 0 0 
4. Tharpagam 0 0 
5. Santhigam 19 47.5 
 
 
 
Figure 14 c:Bar diagram reference to kabam derangement 
 
Inference: 
 `According to Kabam, derangement of Avalambagam was 100%, Kelathagam was 
deranged in 90% and sandhigam 47.5% . 
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Table 16 : Distributions of patients with Neerkanamantham   according 
to Udal kattugal 
S.No Udal kattugal No.of Cases Percentage 
1. Saaram 40 100 
2. Senneer 0 0 
3. Oon 0 0 
4. Kozhuppu 0 0 
5. Enbu 0 0 
6. Moolai 0 0 
7. 
Sukkilam  / 
Suronitham 
0 
0 
 
 
Figure 15:Bar diagram reference to Udarkattugal 
 
Inference:  
Saram was affected in 100% of cases, Senneer was affected in 40% of cases. 
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Table 17 : Distributions of patients with Neerkanamantham   according 
to Enn vagai thervu  
S.No 
Enn Vagai 
Thervugal 
No.of Cases Percentage 
1 Naa 8 20 
2 Niram 0 0 
3 Mozhi 10 25 
4 Vizhi 18 45 
5 Sparisam 5 12.5 
6 Malam  7 17.5 
7 Moothiram 0 0 
8 Naadi :Vathapitham 28 70 
9 Pithavatham 9 22.5 
10 Pithakabam                   3 7.5 
 
 
Figure 16:Bar diagram reference to Ennvagai thervu 
Inference: 
Out of 40 cases  pale ,coated and slightly dried tongues were noted in 20 % cases. 
Sore throat and hoarsness of voice noted in 25% of cases. Pallor of the eyes was noted in 
45 % of the cases.Low grade fever was observed in 12.5% of cases. 17% of the cases 
were affected by irregular bowel habits. 
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Naadi: 
Inference: 
In Naadi, Vathapitham was observed in 70 % of cases, Pithavatham was observed 
in 22.5 % of cases, Pithakabam was observed in 7.5 % of cases.   
 
Table18: Distribution of patients with Neerkanamantham according to 
observation of Neikuri analysis 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17:Bar diagram reference to Neerkuri 
Inference 
According to Neikuri, Vatha neer was observed in 72.5% of cases, pitha neer was 
observed in 15% of cases, Kaba neer was observed in 12.5% of cases. 
S.No 
Character of 
urine 
Neikuri 
Reference 
No.of Cases Percentage 
1. 
Spreads like 
snake 
Vatha Neer 
29 
72.5 
2. 
Spreads like 
ring 
Pitha Neer 
6 
15 
3. Static as pearl Kaba Neer 5 12.5 
4. 
Spreads like 
snake and ring 
Thontha Neer 
0 
0 
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Table 19 a : Distribution of patients with Neerkanamantham according 
to Clinical features 
19 (a)-COUGH ( MODIFIED LEISTER COUGH ASSESSMENT SCALE ) 
Sl.No 
COUGH 
ASSESSMENT 
No of  patients 
observed 
before 
treatment 
percentage 
No of  
patients 
observed after 
treatment 
 
Percentage 
1. Presence of chest 
pain or abdominal 
pain during cough 
13 32.5 4 10 
2 Presence of sputum 
production 
35 87.5 8 20 
3 Speech interruption 
due to cough 
22 55 7 17.5 
4 Cough on exposure 
to dust , smoke 
26 65 12 30 
5 Sleep disturbances 
due to cough  
28 70 10 25 
6 Cough present at 
rest 
10 25 4 10 
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Figure 18 a:Bar diagram reference to Cough assessment  scale 
 
Inference: 
Among the 40 cases,32.5% of the patients had Chest or abdominal pain during 
cough, 87.5 % of patients had sputum production during cough, 55% Pateints had  speech 
interruption due to cough,. 65% of patients had cough on exposure to smoke , dust 
etc..70% of the patients had sleep disturbances due to cough, and 25 % had cough at rest 
,at the base of treatment.  At the end of the treatement Chest or abdominal pain during 
cough in 10 % of cases,sputum production during cough in 20% of cases , speech 
interruption due to cough in 17.5% of cases , cough on exposure to smoke , dust etc..in 30 
% of cases, sleep disturbances due to cough in 25 % of cases,  cough at rest in 10%of 
cases was noted. 
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Table 19 (b) RHINITIS QUESSTIONNAIRE 
 
Sl.No QUESTIONS 
No of  patients 
observed 
before 
treatment 
Percentage 
 
No of  
patients 
observed after 
treatment 
 
Percentage 
 
1. Watery / thick 
nasal discharge 
38 95 9 22.5 
2 Sneezing 37 92.5 10 25 
3 Nasal obstruction 37 92.5 9 22.5 
4 Itchy nose  24 60 5 12.5 
5 Sleep disturbances  7 17.5 1 2.5 
6 Symptoms present 
on exposure to 
chill,water,smoke 
etc 
11 27.5 6 15 
 
 
 
100 
 
 
Figure 18 b:Bar diagram reference to Rhinitis assessment 
 
Inference 
Among 40 cases , 95% of patients  had watery / thick nasal discharge ,92.5% of 
cases had sneezing ,92.5 % 0f cases had nasal obstruction , 60 % of cases had itchy nose , 
17.5% of cases had sleep disturbances, 27.5% of cases had symptoms on exposure to 
chillness .After treatment , watery / thick nasal discharge in 22.5 % of cases ,sneezing in 
25% ,0f cases and nasal obstruction in 22.5 % of cases , itchy nose in 12.5% of cases , 
sleep disturbances in 2.5 % of cases and symptoms on exposure to chillness in 15% of 
cases was noted. 
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Table 19(c)- OTHER CLINICAL SYMPTOMS 
Sl.No QUESTIONS 
No of  patients 
observed 
before 
treatment 
percentage 
No of  
patients 
observed after 
treatment 
 
Percentage 
1. Sneeze 37 92.5 10 25 
2 Sore throat 19 47.5 3 7.5 
3 Loss of appetite 36 90 0 0 
4 Fatigue  18 45 2          5  
5 Diarrhea  6 15 0 0 
6 low gradefever                                                 7 17.5 0 0 
 
 
Figure 18 c :Bar diagram reference to Other clinical symptoms 
 
Inference 
Among 40 cases , 92.5% of patients  had sneezing ,47.5% of cases had sore throat ,90 % 
0f cases had poor appetite, 45 % of cases had fatigue, 15% of cases had diarrhoea, 17.5% 
of cases had low grade fever .After treatment , sneezing in 25 % of cases , sore throat in 
7.5% 0f cases and fatigue in 5% of cases , was noted. 
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STATISTICAL ANALYSIS 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. STATA software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross- tabulations were 
performed. Bar diagram, Pie charts were used to describe the value of different variables 
for pictorial representation. The quantity variables were expressed as Mean and standard 
deviation and qualitative data as percentage. A probability value of less than 0.05 was 
considered to indicate as statistical significance. Paired „t‟ test was performed for 
determining the significance between before and after treatment. 
 
Clinical Symptoms score of NEERKANA MANDHAM before and after treatment 
Treatment Mean ± Std Dev 95% of C.I Significance (t, p) 
Before (40) 10.28± 1.44 9.8 to 10.7 43.83 
P <0.0001 After (40) 0.9± 0.84 0.63 to 1.16 
 
 The mean and standard deviation of clinical symptoms score of NEERKANA 
MANDHAM before and after treatment were 10.28 ± 1.44 and 0.9± 0.84 respectively, 
which is statistically highly significant. 
The reduction of clinical symptoms after the treatment is highly significant ( P 
<0.0001).The reduction in the symptom is 91.25 % at the end of the treatment. 
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6.DISCUSSION 
 
 Neerkanamantham is one of the  most common acquiredillness of the children 
which hinders  their day to day activities.It is characterized by cough, running 
nose,sneeze, low grade fever, headache, fatigue, and diarrhea. Neerkanamantham is 
more or less similar tocommon cold in modern terms. 
 
The simple and highly efficient drug which has been mentioned in Siddha 
literature for the management of Neerkanamantham was selected and the study was 
conducted after the proposal and it was screened by the Screening committee of National 
Institute of Siddha and the trial was also approved by the Institutional Ethical Committee 
(IEC) approval no : NIS/IEC/8-14/19. Following that, the trial was registered in Clinical 
trial registry of India  registration no : CTRI/2016/03/00675. 
 
The ingredients of the trial drugs were collected by the author from their sources 
in field visit and from raw drug shop. After proper identification of the fruit it was 
collected and submitted for  authentication in theMedicinal botany department in NIS, 
Chennai 47.After proper authentication,the trial drug was prepared by the author in the 
Gunapadam practical laboratory of National Institute of Siddha. The trial drug was 
prepared by the standard operating procedure as mentioned in the protocol. 
 
Physico chemical analysis was done as a preliminary evaluation on trial drug  
Karai rasayanam.Rancidity is the important qualitative parameter to check the quality of 
the sample.The method of measuring  the decomposition (or)degradation of  fatty acid is 
called rancidity.Since the rancidity value is negative the quality of the sample is 
good.Peroxide value is a measure of present state of rancidity of a sample,that is the 
decomposition rate of fattyacid present in the sample.Here the peroxidase value is 
negative, which means the drug is stable .The Peroxide value also helps in determining 
the age of the sample. 
 
Iodine value, Saponification value is used to measure the relative degree of 
unsaturated fatty acid in the sample.The saponification value indicates the mean 
molecular weight of fatty acid of triglycerides comprising of fat.Lower the saponification 
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value larger the molecular weight of fatty acids and triglyceride vice versa.Since the 
Iodine&saponification value is  17.89 and 232.21 respectively,  which interprets low 
molecular weight of the fattyacids and triglycerides.The refractive index is a measure of 
purity of a sample.It is a ratio of  velocity of light in vacuum.If any adulteration is present 
in the sample the refractive index will increase or decrease .which is  very helpful in 
determination of unsaturation. Refractive index increases with increase in unsaturation. 
Since the refractive index is  1.457  it interprets that there is  no adulteration in the sample 
and degree of unsaturation is low. The fat content in trial drug Karai Rasayanam is 60.85 
% . 
 
In the  In-vitro Anti inflammatory activity of Karai rasayanam , protein (Albumin) 
denaturation the result obtained from the present study clearly indicates the test drug                          
was effective in inhibiting  heat induced albumin denaturtion. Maximum inhibition is 
about  93.87 % was observed at 50 mg/ml when compared to that of diclofenac sodium 
and standard anti inflammatory agent with the maximum inhibition is about 95.2%  at the 
concentration  of  1.250 mg/ml.  
 
The inhibiting concentration (IC50) values of karai rasayanam and acetylsalicylic 
acid against membrane stabilization is 5.762 mg/ml and 0.1918 mg/ml. 
 
The chemical analysis revealed the presence of effective minerals such as 
chloride, ammonia ,sulphate , magnesium , calcium , phosphate , aluminium , reducing 
sugars and alkaloids. 
 
The  study was started in National Institute of Siddha, totally 93 cases were 
screened and forty three cases were recruited and given treatment in the out patient and 
inpatient department, based on the clinical features which is mentioned in textbook of 
Balavagadam. Out of these forty cases three cases were excluded from the study due to 
poor drug compliance and no  follow up. 
 
In the initial stage of the study , whoever fulfills the inclusion criteria during 
screening was in the list of trial. During each recruitment , after confirming that the 
informants are reliable they are explained about the study and provided information sheet. 
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Then after getting the proper concern from them ,the author recruits the patient and starts 
to fill the case sheet.The diagnosis is done based on clinical observation. 
  
The clinical diagnosis isarrived and treated with the drug “KARAI 
RASAYANAM”.It has been distributed in a clean and labeled container.Informants were 
clearly explained that if they find any difficulty they may contact the author at any time 
and they are free to withdraw from the trial .They are adviced to have a clinical visit on 
eight th day to record the prognosis. 
 
Since the medicine is easily palatable and gives a good relief from symptoms most 
of the patients had a regular visit and they had  co operated for the further follow up.One 
or two due to some domestic issues they couldn‟t co operate for the further follow 
ups.The patients were very much interested and the author had atmost 95% good drug 
compliance and follow up. 
 
The treatment was aimed at normalizing the deranged thodams and providing 
relief from symptoms. Before treatment the patients were advised to adapt lifestyle 
modifications such as oil bath weekly twice, follow good dietary regimen, avoid 
unhygienic road side foods,refrigerated items etc,.. 
 
The patients were treated with trial drug KARAI RASAYANAM  for 7 days. 
Patients were instructed to take the medicines regularly and advised to follow pathiyam 
and to avoid exposure to allergic substances if any. To make them ease each patient was 
issued a diet form. Patients were asked to visit the hospital on 8
th
 day.on that day the 
clinical symptoms after treatment has been recorded in the case sheet carefully.the 
clinical scores were  calculated and explained to the parents too. 
 
After completion of the study, the patients were advised to visit the Out-Patient 
ward of Department of Kuzhanthai Maruthuvam for 1 month for follow-up.  
 
The results observed during the study period are discussed as follows.This study 
evaluates the effect of “KARAI RASAYANAM” in relieving the symptoms of 
Neerkanamantham. 
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CLINICAL REVIEW 
Age: 
In this clinical study , Out of 40 patients, 75% of cases were 3-4 years, 25% were 
5-7 years. The author recruited the cases as per inclusion and exclusion criteria ,whoever 
reported to the opd at the time of active study period only.so the predominance of age 
couldn‟t be attributed to the epidemiological facts. 
 
Sex 
Out of 40 patients 50% patients weremale children and 50% patients were female 
children. In distribution of sex it was observed that there was no predominance among the 
boys and girls,in this study.Similar to age criteria gender also cannot be predicted since 
recruitment is only in the active study period. 
 
Socio-economic status: 
Overall in 40 cases, about 50% patients were under lower income group, 32% 
patients were under middle income group and 18% patients were under high income 
group.  The highest incidence occurred in lower income group,since they do not follow 
good food habits,children are more exposed to the polluted environment,proper hygiene 
status cannot be maintained. 
 
Seasonal variation: 
According to Paruvakalam high incidence of cases 37.5% were reported in 
Kaarkaalam and 35% were reported in Pinpanikalam,20% were reported in mudhuvenil 
kaalam.Since during rainy season most of the children prone to to get infected,the highest 
incidence is in kaarkaalam and as the author conducted the clinical study through out all 
the seasons the incidence rate in individual seasons varied. 
 
Food habits: 
According to food habits 80% of cases had mixed diet, and 20% had vegetarian 
diet. The highest incidence of cases was observed in mixed diet of food habits.during the 
intake of non vegetarian foods the children are more prone to indigestion,which may lead 
to over reaction of small infections. 
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Nilam: 
 Among 40 patients, 82.5% were from Neithal land, 15% from Marutham land, 
2.5% from Mullai land.Since the study place is situated at Neidhal land,the patients from 
this land is the most. 
 
Vali (Vatham): 
Due to the derangement of different vatha the following symptoms occur. Pranan 
was affected in 100% cases and causes cough. Samanan was affected in 100% cases and 
causes poor appetite. Uthanan was affected in 100% of cases and cause cough, Kirukaran 
was affected in 100% and causes sneeze and rhinorrhoea. 
 
 
Azhal (Pitham): 
Due to the derangement of Pitham the following symptoms occur. Analapitham 
was affected in 90% and causes poor appetite. Ranjakam was affected in 45% and causes 
pallor. Saathakam was affected in 47.5% and causes fatigue and malaise. 
 
Iyyam (Kabam): 
Deranged Avalambagam was affected in 100% and causes cough Kilethagam was 
affected in 90% and causes poor appetite. 
 
Ezhu udarkattugal: 
In Ezhu udal kattukal, Saram was affected in 100% and causes malaise, fatigue., 
cheneer was affected in 40% causes anaemia, anorexia and generalized weakness of the 
body. 
 
Envagai thervugal: 
According to this study, 
Niram was affected in 20% of cases (pallor) 
Vizhi were affected in 4.5% of cases (pallor), 
Sparisam was affected in 12.5% of cases (raised temperature) 
Mozhi was affected in 17% of cases (sore throat ) 
Malam was affected in 17% of cases (constipation / loose stools ) 
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Naadi: 
Vathapitham was observed in 70 % of cases, 
Pithavatham was observed in 22.5% of cases, 
Pithakabam was observed in 7.5% of cases. 
According to naadi, high Distribution observed in vadha pitham, pitha vadham and pitha 
kabam naadi. In Siddha literature, the character of vali Azhal is mainly constipation, poor 
appetite, abdominal pain, indigestion and nausea. 
 
 
Neerkuri: 
Regarding moothiram, neerkuri showed straw coloured urine in all cases. 
 
Neikuri: 
In the present study, 72.5% of patient had vatha neikuri, 15% was observed as 
pitha neikuri and 12.5% was observed as kaba neikuri. According to this neikuri, vadham 
was dominately affected. 
 
Distribution according to clinical presentation  
Cough – modified leister cough assessment scale 
Among the 40 cases ,32.5% of the patients had Chest or abdominal pain during 
cough, 87.5 % of patients had sputum production during cough ,55% Pateints had  speech 
interruption due to cough ,65% of patients had cough on exposure to smoke , dust etc. 
70% of the patients had sleep disturbances due to cough, and 25 % had cough at rest ,at 
the base of treatment. 
 
Rhinitis - quesstionnaire 
Among 40 cases ,95% of patients  had watery / thick nasal discharge ,92.5% of 
cases had sneezing ,92.5 % 0f cases had nasal obstruction ,60 % of cases had itchy nose , 
17.5% of cases had sleep disturbances,27.5% of cases had symptoms on exposure to 
chillness.  
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Other clinical symptoms 
Among 40 cases ,92.5% of patients  had sneezing , 47.5% of cases had sore throat 
90 % 0f cases had poor appetite,45 % of cases had fatigue, 15% of cases had diarrhoea,  
       17.5% of cases had low grade fever 
 
The clinical improvements were accurately noted and further follow up was made in 
outpatient department. 
 
In the management ofcough which is assessed by Modified Leister Cough Scale, 
there is ,  50%good improvement , 45 %  moderate improvement, 5%  mild improvement 
  
In the management of rhinitis which is assessed by Rhinitis Questionnaire ,there is 
67.5% good improvement,30 % moderate improvement, 2.5%   mild improvement 
 
In the management of other symptoms there is,  97.5% good improvement, 1 %          
moderate improvement. 
 
These results were completely  basedon the clinical improvements. 
 
In the other hand , based on the statistical data, 
 
The mean and standard deviation of clinical symptoms score of NEERKANA 
MANDHAMbefore and after treatment were 10.28 ± 1.44 and 0.9± 0.84 respectively, 
which is statistically highly significant. 
 
The reduction of clinical symptoms after the treatment is highly significant ( P 
<0.0001).The reduction in the symptom is 91.25 % at the end of the treatment. 
Hence the efficacy of the trial drug Karai rasayanam in the management of Neerkana 
mandham ,which is observed clinically and statistically is found to be effective. 
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7.SUMMARY 
 
Patients attending the out patient department of National Institute of Siddha having 
the complaints of Neerkana mantham was diagnosed clinically, and were observed  . 
Classical symptoms of   Neerkana mantham emphasis symptoms of common cold  like 
Cough,  Running Nose ,Sneeze, Low Grade Fever, Headache, Fatigue,  Diarrhoea. 
Clinical diagnosis of Neerkana mantham was   done on the basis  of  the clinical features   
described in Balavagadam text.  
Clinical studies were carried out after obtaining approval from Institutional 
Ethical Committee of National Institute of Siddha and the trial was registered in Clinical 
trial registry of India. The medicines were prepared after obtaining proper authentication 
from Medicinal BotanyDepartment.,Physicochemical analysis,Chemical analysis 
Pharmacological activity (anti – inflammatory ) for the drugs were  performed.  
 The patients with Neerkana manthamwere recruited based on Inclusion and 
Exclusion criteria and a detailed study was done. Separate proforma was maintained for 
each patient along with daily progress chart to monitor the prognosis.            
Thesigns, symptoms, andetiopathogenesisofcommon cold explained 
inmoderndiagnosishavelotof similaritieswiththediseaseentity Neerkana mantham.  
The medicine chosen for clinical study of  Neerkana mantham is Karai 
Rasayanam  internally two times in a day for 7 days.   All  the  patients  were  adviced 
diet  regimen  during  the  treatment.  
The physico chemical analysis reveals the rancidity and peroxidase value as 
negative,high saponification value,good refractive index and moderate acid value .The 
chemical analysis of drugs shows the presence of chloride , ammonia ,sulphate , 
magnesium , calcium , phosphate , aluminium , reducing sugars and alkaloids.The trial 
drug shows a potent anti inflammatory activity. The patients have not complained of any 
adverse effects or difficulties during the course of treatment. Thus the drug is found to be 
safe and effective in the management of Neerkana mantham.  
The  clinical efficacy  of  the  drug  Karai rasayanam in the management of 
Neerkana mandham in children was  analyzed  statistically  on  all  the  symptoms 
mentioned  in  the  assessment  criteria and it was resulted as follows ,  
In the management ofcough which is assessed by Modified Leister Cough Scale, 
there is, 50%good improvement , 45 %  moderate improvement, 5%  mild improvement 
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 In the management of rhinitis which is assessed by Rhinitis Questionnaire ,there is 
67.5% good improvement,30 % moderate improvement, 2.5%   mild improvement 
In the management of other symptoms there is,  97.5% good improvement, 1 %          
moderate improvement. 
These results were completely  basedon the clinical improvements. 
The mean and standard deviation of clinical symptoms score of NEERKANA 
MANDHAMbefore and after treatment were 10.28 ± 1.44 and 0.9± 0.84 respectively, 
which is statistically highly significant. 
The reduction of clinical symptoms after the treatment is highly significant ( P 
<0.0001).The reduction in the symptom is 91.25 % at the end of the treatment. 
Theobservation both clinically and statistically made duringtheclinicalstudy explores 
thatthetraildrugKarai rasayanamwasclinicallyeffective in the management of Neerkana 
mandham in children. 
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8.CONCLUSION 
 
All the 40 patients clinically diagnosed as Neerkana mantham were treated with 
Karai rasayanam internally two times in a day for 7 days in Kuzhandhai Maruthuvam 
department, National Institute of Siddha, Chennai- 47. 
Theingre dients of  Karai rasayanam are purely herbal , cost effective and these 
compounds may serve as potentially useful drug at a lower cost since most of them had 
anti-inflammatory, anti-pyretic, antibacterial activity. 
The medicine has many properties to control the signs and symptoms of Neerkana 
mantham. During  the course of treatment, no adverse reactions were observed. The 
clinical assessment of the disease were found to be good which was assessed by the 
clinical results and the modified leisters cough assessment scale & rhinitis 
questionnaire. 
Statistically,the reduction of clinical symptoms after the treatment is highly 
significant ( P <0.0001).The reduction in the symptom is 91.25 % at the end of the 
treatment. 
 The observation both clinically and statistically made during the clinical study 
explores that the trail drug Karai rasayanam was clinically effective in the management 
of Neerkana mandham in children. This has, inturn, provided a golden opportunity or 
new drug established in the managementof  Neerkana mantham. 
Hence the author strongly recommends that this trial drug karai rasayanam is 
very cost effective, easily palatable , which shows a dramatic effect towards the disease 
Neerkana mandham can be given to children without any hesitations,and to make a 
further research works in the complete analysis of this awesome herbal formulation 
given by the Siddhars. 
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POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A CLINICAL EVALUATION OF “KARAI RASAYANAM”FOR NEERKANA 
MANTHAM IN CHILDREN- AN OPEN CLINICAL STUDY. 
                                                    FORM II PATIENT INFORMATION SHEET 
 
Name of Principal Investigator       :______________________________ 
Name of the institute                        : National Institute of Siddha, 
                                                     Tambaram Sanatorium, 
                                                     Chennai-47. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
 
I, ________________________________________Studying as PG Scholar at 
National Institute of  Siddha, Tambaram Sanatorium is doing a trial on the study  
“NEERKANA MANTHAM”. This is a most common respiratory disease in children. In this 
regard, I am in a need to ask you few questions. I will maintain confidentiality of your 
comments and data obtained. There will be no risk of disclosing your identity and no 
physical, psychological or professional risk is involved by taking part in this study. Taking 
part in this study is voluntary. No compensation will be paid to you for taking part in this 
study. 
           You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions. 
             If you agree your child to be a participant in this study, he/she will be included in the 
study primarily by signing the consent form and then you will be given the internal medicine 
KARAI RASAYANAM [4ml-twice a day]. 
 
The information I am collecting in this study will remain between you and the principal 
investigator (myself). I will ask you few questions through a questionnaire. I will not write 
your name on this form. I will use a code instead.  
The questionnaire will take approximately 20 minutes of your time. 
If you wish to find out more about this study before taking part, you can ask me all 
the questions you want or contact Dr.P.ALARMEL MANGAI, PG Scholar cum principal 
investigator of this study, attached to National Institute of Siddha,Chennai-47. You can also 
contact the Member-secretary of Ethics committee, National Institute Siddha,Chennai 
600047, Tel no : 91-44-22380789, for rights and participation in the study.  
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                                                         ANNEXURE III 
 
                                         NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A CLINICAL EVALUATION OF “KARAI RASAYANAM”FOR NEERKANA 
MANTHAM IN CHILDREN- AN OPEN CLINICAL STUDY. 
                                                Form III – CONSENT FORM   
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent/guardian 
Signature  _________________ 
Date   _________________ 
Name  ________ _________ 
CONSENT BY PARENT 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my son/daughter body functions. 
 I am aware of my right to withdraw my son/daughter out of the trail at any time 
during the course of the trail without having to give the reasons for doing so.  
 I, exercising my free power of choice, hereby give my consent to include my 
son/daughter as a subject in the clinical trial of „KARAI RASAYANAM‟ for the treatment 
of „NEERKANA MANTHAM‟  
Date :       Signature  __________________ 
      Name   __________________ 
Date :       Signature of witness  __________________ 
      Name   __________________ 
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ANNEXURE IV 
 
NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A CLINICAL EVALUATION OF “KARAI RASAYANAM”FOR NEERKANA MANTHAM IN CHILDREN- 
AN OPEN CLINICAL STUDY. 
Form IV-  CASE REPORT FORM 
1.HISTORY TAKING                                  Demographic data 
 Patient Id : OP/IP No. Visit Date : (__/__/____) 
Name :  
Age    :  
Gender                Male             Female Date Of Birth : (__/__/____) 
Father/ Mother /Guardian Name : 
 
 
Fathers/Mother Occupation : 
 
 
 Monthly  Income : 
 
 
Religion : 
 
 
 
Socioeconomic Status : 
 
 
 Informant : 
 
 
 
 
Postal Address: 
Contact No: 
  
1.COMPLAINTS AND DURATION            
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
------------------------- 
1. H/O PRESENT ILLNESS  
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
------------------------- 
2.  HISTORY OF PAST ILLNESS  
 History /Symptoms/Signs  Yes  No  If, Yes Details 
Any Similar Complains  
Bronchial Asthma 
Dust Allergy 
 Hospitalization 
Any other        _____________ 
Family History 
Any Hereditary/ Familial Disease     Yes                      No 
 If Yes, Details --------------------------------------------------------------------------  
Immunisation History  
 Immunization   complete          Incomplete         Complete but time lag 
Food habits: 
1. Veg  2. Non-Veg  3. Mixed 
General Examination 
1. Pallor    YES  NO 
2. Jaundice   YES  NO 
3. Cyanosis   YES  NO 
4. Clubbing   YES  NO 
5. Pedal oedema   YES  NO 
6. Lymph adenopathy  YES  NO 
Vital signs:- 
1. Pulse rate / mint                - 
2. Heart rate / mint               - 
3. Respiratory Rate / mint    - 
4. Temperature                     - 
Anthropometry:- 
          Height 
          Weight 
            CLINICAL EXAMINATION:                  
  RESPIRATORY SYSTEM 
  INSPECTION: 
SHAPE OF THE CHEST: Normal        Barrel-Shaped          Pigeon chest           Funnelshaped                                                                  
                                             Thoracickyphoscoliosis 
 TRACHEAL POSITION:Normal         Trails sign positive 
  APICAL IMPULSE: Normal          Affected 
RESPIRATORY MOVEMENT:  Respiratory rate:______/minute 
                                                       Rhythm:  Normal          Deep and rapid respiration                                                                                                                                                                                                                                       
.                                                                      Irregularly regular 
                                                      Inter costals space:  Normal           Bulge           Indrawing 
CHEST WALL:   Normal         Bulge           Depression 
VISIBLE PULSATIONS:  Present          Absent 
DISTENDED CHEST VEINS: Present           Absent 
 
b)PALPATION: 
 TRACHEAL POSITION:Normal         Trails sign positive 
  APICAL IMPULSE: Normal          Affected 
TENDERNESS :        Yes              No 
             If yes___________ 
TACTILE VOCAL FREMITUS: Normal and equal        Increased         Decreased 
MOVEMENT OF THE CHEST WALL: Symmetrical          Asymmetrical 
SPINE :    Normal           Kyphosis           Scoliosis        Lordosis 
c) PERCUSSION:         
Percussion on all over area:   Normal         Hyper resonance         Dullness                                                                          
d)   AUSCULTATION: 
Intensity of breath sounds: Normal/decreased/increased __________ 
Adventitious sounds 
 Wheeze   Crepitations  Rub  None of above  
Vocal resonance: Normal/ Increased/ Decreased ______________ 
EXAMINATION OF NAILS: 
1.  Pitting:     Present    Absent 
2.   Thickening:    Present                   Absent 
3.  Collection of Hyperkeratotic debris: Present                Absent 
4.  Separation of distal portion of nail: Present                Absent 
EXAMINATION 
Joint Involvement                              :Yes  No         
Other systems:                     
Cardio vascular system  : Normal               Affected 
Gastro intestinal system:   Normal           Affected 
Musculo skeletal system: Normal             Affected 
Central nervous system: Normal               Affected 
Endocrine system:          Normal                Affected 
                        SIDDHA ASSESSMENT 
Nilam:-  
 
Kurinji  Mullai  Marutham      Neithal   Paalai 
 
Kaala Iyalbu:-  
 
 Kaarkalam    Koothirkaalam  Munpanikaalam  
 Pinpanikaalam            Illavenirkaalam          Muthuvenirkaalam 
Yaakai 
 Vatham          Vatha Pitham           Vatha Kabam 
 Pitham    Pitha vatham   Pitha Kabam 
 Kabam             Kaba Vatham   Kaba Pitham 
Gunam  
 Sathuvam   Rasatham   Thamasam 
 
 
Pori / Pulangal 
  Normal Affected          Remarks 
Mei / unarvu 
Vaai / suvai  
Kan / parvai  
Mooku / natram 
Sevi / olli 
 
Kanmendhirium / Kanmavidayam 
 
 
                                              Normal           Affected       Remarks 
 
Kai / dhanam 
Kaal / ghamanam 
Vaai / vaaku 
Eruvai / visarkam 
Karuvai / anantham 
 
Uyir Thathukkal 
Vatham: 
   Normal   Affected  Remarks 
Pranan  
Abanan 
Viyanan  
Uthanan 
Samanan 
Nagan  
Koorman 
Kirukaran  
Devathathan   
Dhanajeyan      
Pitham  
   Normal Affected  Remarks 
Analam  
Ranjagam    
Saathagam   
Alosagam  
Prasagam 
Kabam  
   Normal Affected  Remarks 
Avalambagam    
Kilethagam   
Pothagam  
Tharpagam   
Samthigam  
Udalthathukkal 
   Normal Affected  Remarks 
Saaram 
Senneer  
Oon  
Kozhuppu 
Enbu 
Moolai 
Sukilam / Suronitham   
Envagai Thervugal  
                            Normal  Affected  Remarks 
Naa  
 Niram 
 Thanmai 
 Suvai 
Niram   
Mozhi   
Vizhi  
 Niram 
 Thanmai 
 Paarvai 
Sparisam  
Malam 
 Niram   Normal Affected 
 Nurai   Normal Affected 
 Elagal   Normal Affected 
 Erugal   Normal Affected 
Moothiram 
 Neerkuri:       Niram   Normal Affected 
  Edai   Normal Affected  
  Nurai             Normal  Affected 
  Manam            Normal  Affected  
  Enjal Neikuri  Normal Affected   
 
Neikuri: 
  Vatham  
  Pitham 
  Kabam 
  Others 
Naadi: 
 
Thani Nadi        Vadham       pitham    kabam 
 
Thontha Nadi 
           Vatha pitham          Pitha vatham      Pitha kabam Kaba pitham 
 
Thoda Nadi 
 Vatha kabam          Kaba vatham 
 
Mukkutra  Nadi 
Diagnosis   --------------------------------------   
 Drug issued:___________________________ 
   
 Date  : ___________________     Station : ___________________ 
                 
2.CLINICAL ASSESSMENT FORM  
 
MODIFIED LEICESTER COUGH 
QUESTIONNAIRE(Each item 
carries 5 points) 
BEFORE 
TREATMENT  
DATE: 
AFTER 
TREATMENT 
DATE: 
 
 
S.no        QUESTIONS YES NO YES NO 
1. 
 
2. 
3. 
 
4. 
 
5. 
6. 
Presence of chest pain or 
stomach pain during cough 
Presence of sputum 
production during cough 
Interruption of speech due to 
cough 
Presence of cough on 
exposure to dust,smoke etc    
Sleep disturbances due to 
cough 
Cough present at rest                                                                         
    
        TOTAL SCORE  OUT OF 30   
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                               
  
 
 
 
 
               
 
 
 
 
 
       
  
 
 
 
 
 
 
TEMPERATURE 
ASSESSMENT OF  BODY TEMPERATURE (AXILLARY REGION) USING CLINICAL 
THERMOMETER.  
 
 
DATE MORNING EVENING 
D1    
D4    
D7    
 
 
  
RHINITIS 
QUESTIONNAIRE(Each item 
carries 5 points) 
BEFORE 
TREATMENT  
DATE: 
AFTER 
TREATMENT 
DATE: 
 
 
S.no        QUESTIONS YES NO YES NO 
1. 
2. 
3. 
4. 
5. 
 
6. 
Watery / thick nasal 
discharge 
Sneezing 
Nasal obstruction 
Itchy nose 
Sleep disturbances 
Symptoms present on 
exposure to chill 
water,smoke etc                                                                         
    
   TOTAL SCORE  OUT OF 30   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                        
  
OTHER CLINICAL 
SYMPTOMS (Each item 
carries 5 points) 
BEFORE 
TREATMENT  
DATE: 
AFTER 
TREATMENT 
DATE: 
       QUESTIONS YES NO YES NO 
Sneeze 
Sore throat 
Poor appetite 
Fatigue 
Diarrhea 
Low grade fever                                                                        
    
   TOTAL SCORE  OUT 
OF 30 
  
                                                          ANNEXURE V 
 
NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A CLINICAL EVALUATION OF “KARAI RASAYANAM”FOR NEERKANA 
MANTHAM IN CHILDREN- AN OPEN CLINICAL STUDY. 
                                                Form V – DRUG COMPLIANCE   
1. S.l. No: 2. OP/ IP No  : 3. Name: 
4. Age: 5. Gender: 6. Date of Enrollment: 
7. Date of completion: 8. Informant: 9. Reliablity: 
 
NAME OF THE DRUG  KARAI RASAYANAM 
FORM OF THE DRUG    SEMI SOLID 
ADMINISTRATION         PER ORAL 
DOSE & DURATION        4ml  DAILY FOR 7 DAYS  
NO. OF DRUG BOTTLES GIVEN  ____ 
NO. OF DRUG BOTTLES RETURNED  ____   
 
DAY DATE 
OF          
DRUG    
INTAKE 
MORNING 
  
EVENING  
  
   
DAY 1     
DAY 2    
DAY 3    
DAY 4    
DAY 5    
DAY 6    
DAY 7    
 
Signature of Principal Investigator : 
Date: 
Station: 
 
                                                          ANNEXURE VI 
                                              NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A CLINICAL EVALUATION OF “KARAI RASAYANAM”FOR NEERKANA 
MANTHAM IN CHILDREN- AN OPEN CLINICAL STUDY. 
                                                Form VI    WITHDRAWL FORM   
 
1. S.l. No: 2. OP/ IP No  : 3. Name: 
4. Age: 5. Gender: 6. Date of Enrollment: 
7. Date of completion: 8. Informant: 9. Reliablity: 
 
 
Date of trial commencement    : 
Date of withdrawal from trial   : 
Reason(s) for withdrawal   : Yes/ No  
Long absence at reporting   : Yes/ No 
Irregular treatment     : Yes/ No 
Shift of locality      : Yes/ No 
Complication adverse reactions if any : Yes/ No 
Exacerbation of symptoms   : Yes/ No 
 Patient not willing to continue             : Yes/ No 
 
 
 
Signature of Principal Investigator : 
 
 
Date:        
Station : 
  
                                                 ANNEXURE VI1 
                                            NATIONAL INSTITUTE OF SIDDHA 
 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A CLINICAL EVALUATION OF “KARAI RASAYANAM”FOR NEERKANA 
MANTHAM IN CHILDREN- AN OPEN CLINICAL STUDY. 
                                                Form VII – ADVERSE REACTION FORM   
1. S.l. No: 2. OP/ IP No  : 3. Name: 
4. Age: 5. Gender: 6. Date of Enrollment: 
7. Date of completion: 8. Informant: 9. Reliablity: 
 
 
Name       : 
Age       : 
Gender    : 
OPD/ IPD No    : 
Registration No    : 
Date of trial commencement  : 
Date of withdrawal from trial   : 
Description of adverse reaction  : 
 
 
      
Signature of Principal Investigator : 
                         
Date:    
Station :  
                                                  ANNEXURE  VIII 
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  SIDDHA DRUGS 
 
 
 
 
Please note:  i.  All consumers / patients and reporters information will remain confidential. 
         ii. It is requested to report all suspected reactions to the concerned, even 
if  
             it does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 
 Geographical area: 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
 
3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
 
Medicine Dail
y 
dose 
Route of 
administration 
& Vehicle – 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha 
 
 
 
 
     
Any other system 
of medicines 
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained 
from 
   
e) Composition of the 
formulation / Part of the drug 
used 
   
 
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or used 
as self medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
 
6. The result  of the adverse reaction / side effect / untoward effects (please complete the 
boxes below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
Signature of the reporter:       Date: 
Please send the completed form to:  
           The Director 
            National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha 
Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 22381314 
        Website : www.nischennai.org  
        Email: nischennaisiddha@yahoo.co.in   
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence of 
ADR   
 
 
 
Date:                                                                              
Station:  
 
Date :      
Date : 
Station : 
Signature of the Investigator: 
Signature of the Lecturer:                                                                                    
 Signature of the HOD 
 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the 
fullest extent.  
 Submission of report will be taken up for remedial measures only not for legal 
claim  
Name & address of the RRC-
ASU / PPC-ASU 
                                                              ANNEXURE IX 
                                             NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
A CLINICAL EVALUATION OF “KARAI RASAYANAM”FOR NEERKANA 
MANTHAM IN CHILDREN- AN OPEN CLINICAL STUDY. 
  FORM IX-DIETARY ADVICE FORM 
 
 THINGS TO TAKE  THINGS TO AVOID 
Milk with palm sugar Refrigerated items 
 
Tulsi leaf juice Tin and can foods,broiler chicken. 
 
Fresh vegetable soups/Country chicken 
or mutton soups 
Cream containing biscuits and cakes 
 
Boiled water/Baked foods like idly Junk and fast foods 
 
Pepper,turmeric and cumin seeds White sugar 
 
    : 
   : 
   , , ,   . 
   , ,     . 
   ,    . 
 , , ,       
  . 
       
    
: 
 , ,     
  ,    . 
    ,   ,  
. 
     . 
     . 
 
ANNEXURE X: CLINICAL ASSESSMENT SCORE 
COUGH: Modified leister cough assessment scale 
RHINITIS : Rhinitis Questionnaire 
S.NO OP.NO    COUGH 
B.T         A.T 
Rhinitis 
B.T         A.T 
Other    symp 
B.T           A.1T 
    TOTAL 
B.T       A.T 
1 C99070 4 1 4 1 3 0 11 2 
2 G32930 4 1 4 1 3 0 11 2 
3 E60581 4 0 2 0 3 0 9 0 
4 F97706 3 0 3 0 3 0 9 0 
5 F20161 4 1 4 1 2 0 10 2 
6 G49608 4 1 4 0 3 0 11 1 
7 F15034 4 1 4 1 2 0 10 2 
8 D68338 4 0 3 0 3 0 10 0 
9 G83727 4 1 4 1 3 0 11 2 
10 G49956 3 1 3 1 3 0 9 2 
11 G59658 4 0 5 1 4 0 13 1 
12 E95595 4 0 5 1 3 0 12 1 
13 G62383 5 1 5 1 4 0 14 2 
14 D31968 4 0 4 0 3 0 11 0 
15 F84856 4 0 4 0 3 0 11 0 
16 H20830 5 1 4 1 3 0 12 2 
17 H20966 4 0 4 0 2 0 10 0 
18 G27250 4 0 4 0 2 0 10 0 
19 F39454 3 0 3 0 2 0 8 0 
20 H21022 3 0 3 0 1 0 7 0 
21 G64753 4 0 4 2 3 0 11 2 
22 G64880 3 1 4 0 3 0 10 1 
23 G10458 4 0 4 0 3 1 11 1 
24 H23458 4 0 3 1 1 0 8 1 
25 G97510 3 0 3 0 2 0 8 0 
26 H20585 3 0 3 0 2 0 8 0 
27 H23728 3 0 4 0 3 0 10 0 
28 H23710 4 1 3 0 3 0 10 1 
29 G59602 4 1 4 1 2 0 10 2 
30 F00837 3 1 4 0 3 0 10 1 
31 H26987 4 1 3 0 2 0 9 1 
32 1805 3 0 4 0 3 0 10 0 
33 H58760 4 1 4 0 2 0 10 1 
34 G85474 4 0 4 0 3 0 11 0 
35 F63689 4 0 4 0 2 0 10 0 
36 E35958 5 1 4 0 3 0 12 1 
37 1858 4 1 5 0 4 0 13 1 
38 F63689 4 0 4 0 2 0 10 0 
39 H59272 4 1 4 0 2 0 10 2 
40 H49795 4 2 4 0 3 0 11 2 
  154 20 152 14 105 1 411 35 
 
 
 
 
 
 
 
  
  
 
 
   
  
 
